<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6770748 - Bicyclonucleoside and oligonucleotide analogue - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Bicyclonucleoside and oligonucleotide analogue"><meta name="DC.contributor" content="Takeshi Imanishi" scheme="inventor"><meta name="DC.contributor" content="Satoshi Obika" scheme="inventor"><meta name="DC.contributor" content="Takeshi Imanishi" scheme="assignee"><meta name="DC.date" content="2001-12-28" scheme="dateSubmitted"><meta name="DC.description" content="An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized."><meta name="DC.date" content="2004-8-3" scheme="issued"><meta name="DC.relation" content="US:5859221" scheme="references"><meta name="DC.relation" content="US:6268490" scheme="references"><meta name="DC.relation" content="WO:1997047636:A2" scheme="references"><meta name="citation_reference" content="Altmann et al., &quot;6&#39;-Carbon-Substituted Carbocyclic Analogs of 2&#39;-Deoxyribonucleosides-Synthesis and Effect on DNA/RNA Duplex Stability,&quot; Tetrahedron, 52(39), 12699-12722 (1996)."><meta name="citation_reference" content="Altmann et al., “6′-Carbon-Substituted Carbocyclic Analogs of 2′-Deoxyribonucleosides—Synthesis and Effect on DNA/RNA Duplex Stability,” Tetrahedron, 52(39), 12699-12722 (1996)."><meta name="citation_reference" content="Beaucage et al. (I), &quot;Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach,&quot; (Tetrahedron Report No. 309) Tetrahedron, 48(12), 2223-2311 (1992).*"><meta name="citation_reference" content="Beaucage et al. (II), &quot;The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications,&quot; Tetrahedron, 49(28), 6123-6194 (1993).*"><meta name="citation_reference" content="Beaucage, &quot;Oligonucleotide Synthesis-Phosphoramidite Approach,&quot; Ch. 3 in Methods in Molecular Biology, vol. 20: Protocols for Oligonucleotide and Analogues, S. Agrawal (ed.), 1993, Humana Press, Totowa, NJ, pp. 33-61.*"><meta name="citation_reference" content="Beaucage, “Oligonucleotide Synthesis—Phosphoramidite Approach,” Ch. 3 in Methods in Molecular Biology, vol. 20: Protocols for Oligonucleotide and Analogues, S. Agrawal (ed.), 1993, Humana Press, Totowa, NJ, pp. 33-61.*"><meta name="citation_reference" content="Herdewijn, &quot;Targeting RNA with Conformationally Restricted Oligonucleotides,&quot; Liebigs Annalen, (Issue No. 9), 1337-1348 (Sep., 1996)."><meta name="citation_reference" content="Lehninger et al., Principles of Biochemistry, Second Edition, Worth Publishers, 1993, only pp. 324-327 supplied.*"><meta name="citation_reference" content="Nielsen et al., &quot;Synthesis and Chemoselective Activation of Phenyl 3,5-Di-O-benzyl-2-O,4-C-methylene-1-thio-beta-D-ribofuranoside: A Key Synthon Towards alpha-LNA,&quot; Chemical Communications, (Issue No. 23), 2645-2646 (Dec. 7, 1998)."><meta name="citation_reference" content="Nielsen et al., “Synthesis and Chemoselective Activation of Phenyl 3,5-Di-O-benzyl-2-O,4-C-methylene-1-thio-β-D-ribofuranoside: A Key Synthon Towards α-LNA,” Chemical Communications, (Issue No. 23), 2645-2646 (Dec. 7, 1998)."><meta name="citation_reference" content="Obika et al., &quot;Synthesis of 2&#39;-O,4&#39;-C -Methyleneuridine and -cytidine. Novel Bicyclic Nucleosides Having a Fixed C3 , -endo Sugar Puckering,&quot; Tetrahedron Letters, 38(50), 8735-8738 (Dec. 15, 1997)."><meta name="citation_reference" content="Obika et al., “Synthesis of 2′-O,4′-C -Methyleneuridine and -cytidine. Novel Bicyclic Nucleosides Having a Fixed C3 , -endo Sugar Puckering,” Tetrahedron Letters, 38(50), 8735-8738 (Dec. 15, 1997)."><meta name="citation_reference" content="Sanghvi, &quot;Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonuceotides,&quot; Ch. 15 in Antisense Research and Applications, Crooke &amp; LeBleu (eds.), CRC Press, Boca Raton, FL, 1993, pp. 273-288.*"><meta name="citation_reference" content="Singh, et al., LNA (locked Nucleic Acids): Synthesis and High-Affinity Nucleic Acid Recognition, Chemical Communications, 1998, 455-456, 4 (Feb. 21, 1998)."><meta name="citation_patent_number" content="US:6770748"><meta name="citation_patent_application_number" content="US:10/029,212"><link rel="canonical" href="http://www.google.com/patents/US6770748"/><meta property="og:url" content="http://www.google.com/patents/US6770748"/><meta name="title" content="Patent US6770748 - Bicyclonucleoside and oligonucleotide analogue"/><meta name="description" content="An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized."/><meta property="og:title" content="Patent US6770748 - Bicyclonucleoside and oligonucleotide analogue"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("XkTsU5v6IaitsAT-1IGIBQ"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("GBR"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("XkTsU5v6IaitsAT-1IGIBQ"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("GBR"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6770748?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6770748"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=gPRnBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6770748&amp;usg=AFQjCNHhSdogKNHak-J0yfLwFyLPEEeX-g" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6770748.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6770748.pdf"></a><a class="appbar-application-grant-link" data-label="Application" href="/patents/US20030105309"></a><a class="appbar-application-grant-link" data-selected="true" data-label="Grant" href="/patents/US6770748"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6770748" style="display:none"><span itemprop="description">An oligo- or polynucleotide analogue having one or more structures of the general formula where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an...</span><span itemprop="url">http://www.google.com/patents/US6770748?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6770748 - Bicyclonucleoside and oligonucleotide analogue</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6770748 - Bicyclonucleoside and oligonucleotide analogue" title="Patent US6770748 - Bicyclonucleoside and oligonucleotide analogue"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6770748 B2</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 10/029,212</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Aug 3, 2004</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Dec 28, 2001</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Mar 7, 1997</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US20030105309">US20030105309</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">029212, </span><span class="patent-bibdata-value">10029212, </span><span class="patent-bibdata-value">US 6770748 B2, </span><span class="patent-bibdata-value">US 6770748B2, </span><span class="patent-bibdata-value">US-B2-6770748, </span><span class="patent-bibdata-value">US6770748 B2, </span><span class="patent-bibdata-value">US6770748B2</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Takeshi+Imanishi%22">Takeshi Imanishi</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Satoshi+Obika%22">Satoshi Obika</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Takeshi+Imanishi%22">Takeshi Imanishi</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6770748.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6770748.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6770748.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (3),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (14),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (67),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (26),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (5)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6770748&usg=AFQjCNHT-4DxzrAdWyAF_YXRibPzaVMz5Q">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6770748&usg=AFQjCNHSBQH7X6j7YXBaHD9ImKBuWj8Ppw">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6770748B2%26KC%3DB2%26FT%3DD&usg=AFQjCNEM4apt54nY9FOFEoa8xeXhxSha3g">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT55306201" lang="EN" load-source="patent-office">Bicyclonucleoside and oligonucleotide analogue</invention-title></span><br><span class="patent-number">US 6770748 B2</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA50702480" lang="EN" load-source="patent-office"> <div class="abstract">An oligo- or polynucleotide analogue having one or more structures of the general formula <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00001.png"> <img id="EMI-C00001" file="US06770748-20040803-C00001.TIF" wi="198.25155" he="77.76405" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00001" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00001.png" class="patent-full-image" width="793" height="311"> </a> </div> <attachments> <attachment idref="CHEMCDX-00001" attachment-type="cdx" file="US06770748-20040803-C00001.CDX"> </attachment> <attachment idref="CHEMMOL-00001" attachment-type="mol" file="US06770748-20040803-C00001.MOL"> </attachment> </attachments> </chemistry> </div>
    <div class="abstract">where B is a pyrimidine or purine nucleic acid base, or an analogue thereof,</div>
    <div class="abstract">is disclosed. The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(2)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-D00001.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6770748B2/US06770748-20040803-D00001.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-D00002.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US6770748B2/US06770748-20040803-D00002.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(5)</span></span></div><div class="patent-text"><div mxw-id="PCLM8712131" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is: </claim-statement> <div class="claim"> <div num="1" id="US-6770748-B2-CLM-00001" class="claim">
      <div class="claim-text">1. A nucleoside analogue of the following formula (I): <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00017.png"> <img id="EMI-C00017" file="US06770748-20040803-C00017.TIF" wi="198.25155" he="77.76405" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00017" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00017.png" class="patent-full-image" width="793" height="311"> </a> </div> <attachments> <attachment idref="CHEMCDX-00017" attachment-type="cdx" file="US06770748-20040803-C00017.CDX"> </attachment> <attachment idref="CHEMMOL-00017" attachment-type="mol" file="US06770748-20040803-C00017.MOL"> </attachment> </attachments> </chemistry> </div>
      <div class="claim-text">where B is an analogue of pyrimidine or purine nucleic acid base, and X and Y are identical or different, and each represents a hydrogen atom, an alkyl group, an alkenyl group an alkynyl group, a cycloalkyl group, an aralkyl group, an aryl group, an acyl group, or a silyl group or a phosphoramidite.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" id="US-6770748-B2-CLM-00002" class="claim">
      <div class="claim-text">2. A nucleoside analogue as claimed in <claim-ref idref="US-6770748-B2-CLM-00001">claim 1</claim-ref>, wherein X and Y each represents a hydrogen atom.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" id="US-6770748-B2-CLM-00003" class="claim">
      <div class="claim-text">3. A mononucleoside amidite derivative as claimed in <claim-ref idref="US-6770748-B2-CLM-00001">claim 1</claim-ref>, wherein X is 4,4-dimethoxytrityl (DMTr), and Y is a 2(N,N-diisopropylcyanoethoxyphosphoramidityl).</div>
    </div>
    </div> <div class="claim"> <div num="4" id="US-6770748-B2-CLM-00004" class="claim">
      <div class="claim-text">4. An oligonucleotide or polynucleotide analogue having one or more structures of the formula (Ia): <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00018.png"> <img id="EMI-C00018" file="US06770748-20040803-C00018.TIF" wi="198.25155" he="75.1275" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00018" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00018.png" class="patent-full-image" width="793" height="300"> </a> </div> <attachments> <attachment idref="CHEMCDX-00018" attachment-type="cdx" file="US06770748-20040803-C00018.CDX"> </attachment> <attachment idref="CHEMMOL-00018" attachment-type="mol" file="US06770748-20040803-C00018.MOL"> </attachment> </attachments> </chemistry> </div>
      <div class="claim-text">where B is an analogue of a pyrimidine or purine nucleic acid base.</div>
    </div>
    </div> <div class="claim"> <div num="5" id="US-6770748-B2-CLM-00005" class="claim">
      <div class="claim-text">5. An oligonucleotide or polynucleotide analogue of the formula (II): <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00019.png"> <img id="EMI-C00019" file="US06770748-20040803-C00019.TIF" wi="214.8363" he="132.98985" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00019" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00019.png" class="patent-full-image" width="859" height="531"> </a> </div> <attachments> <attachment idref="CHEMCDX-00019" attachment-type="cdx" file="US06770748-20040803-C00019.CDX"> </attachment> <attachment idref="CHEMMOL-00019" attachment-type="mol" file="US06770748-20040803-C00019.MOL"> </attachment> </attachments> </chemistry> </div>
      <div class="claim-text">where B<sup>1 </sup>and B are identical or different, and each represents an analogue of pyrimidine or purine nucleic acid base, R is a hydrogen acorn, a hydroxyl group, a halogen atom, or an alkoxy group,</div>
      <div class="claim-text">W<sup>1 </sup>and W<sup>2 </sup>are identical or different, and each represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aralkyl group, an aryl group, an acyl group, a silyl group, a phosphoric acid residue, a naturally occurring nucleoside or a synthetic nucleoside bound via a phosphodiester bond, or an oligonucleotide or polynucelotide containing the nucleotide, n<sup>1 </sup>or n<sup>2 </sup>n are identical or different, and each denotes an integer of 0 to 50, and n<sup>3 </sup>is an integer of 1-50, provided that n<sup>1 </sup>and n<sup>2 </sup>n are not both zero, and that not all of the n<sup>2 </sup>are zero at the same time and when n<sup>1 </sup>and/or n<sup>2 </sup>are or is 2 or more, B<sup>1 </sup>and B need nor be identical, and R need not be identical. </div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES54276299" lang="EN" load-source="patent-office" class="description">
    <p>This is a continuation-in-part application of U.S. patent application Ser. No. 09/904,567, filed on Jul. 16, 2001 now abandoned, which is a continuation of U.S. application Ser. No. 09/380,638, filed Sep. 7, 1999, now U.S. Pat. No. 6,268,490, which in turn was a national stage under 35 U.S.C. 371 of international application PCT/JP98/00945, filed Mar. 9, 1998, which designated the United States, and which international application was not published in the English language.</p>
    <heading>TECHNICAL FIELD</heading> <p>This invention relates to a novel nucleoside analogue and a novel nucleotide analogue, and more particularly, to a nucleotide analogue suitable as an antisense molecule.</p>
    <heading>BACKGROUND ART</heading> <p>In 1978, it was reported for the first time that an antisense molecule inhibited influenza virus infection. Since then, reports have been issued that antisense molecules inhibited the expression of oncogenes and AIDS infection. In recent years, antisense oligonucleotides have become one of the most promising pharmaceuticals, because they specifically control the expression of undesirable genes.</p>
    <p>The antisense method is based on the idea of controlling a unidirectional flow called the central dogma, i.e., DNA→RNA→protein, by use of an antisense oligonucleotide.</p>
    <p>When a naturally occurring oligonucleotide was applied to this method as an antisense molecule, however, it was decomposed with various nucleases in vivo, or its permeation through the cell membrane was not high. To solve these problems, numerous nucleic acid derivatives and analogues have been synthesized, and their studies have been conducted. Examples of the synthesized products include a phosphorothioate having a sulfur atom substituting for an oxygen atom on the phosphorus atom, and a methylphosphonate having a substituting methyl group. Recently, products have been synthesized in which the phosphorus atom has also been substituted by a carbon atom, or the structure of the sugar portion has been changed, or the nucleic acid base has been modified. Any resulting derivatives or analogues, however, have not been fully satisfactory in terms of in vivo stability, ease of synthesis, and sequence specificity (the property of selectively controlling the expression of a particular gene alone).</p>
    <p>Under these circumstances, there has been a demand for the creation of an antisense molecule which is minimally decomposed with a nuclease in vivo, binds to target messenger RNA with high affinity, has high specificity, and can thus efficiently control the expression of a particular gene.</p>
    <heading>DISCLOSURE OF THE INVENTION</heading> <p>The inventors of the present invention designed a nucleic acid analogue with immobilized conformation of the sugar portion in a nucleic acid, which would be useful in the antisense method. They synthesized a nucleoside analogue which will be a unit structure therefor, and confirmed that an oligonucleotide analogue prepared using it was very useful as an antisense molecule.</p>
    <heading>BRIEF DESCRIPTION OF THE DRAWINGS</heading> <p>FIG. 1 is a chart showing the time Course of the ultraviolet absorption (260 nm) of a naturally occurring oligonucleotide (SEQ ID NO:10) decomposed with an exonuclease; and</p>
    <p>FIG. 2 is a chart showing the time course of the ultraviolet absorption (260 nm) of an oligonucleotide of the present invention (X2) (SEQ ID NO:11) decomposed with an exonuclease.</p>
    <p>Details of the present invention will now be described.</p>
    <p>The structure of a nucleoside analogue according to the present invention is a nucleoside analogue of the following general formula (I) <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00002.png"> <img id="EMI-C00002" file="US06770748-20040803-C00002.TIF" wi="198.25155" he="77.76405" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00002" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00002.png" class="patent-full-image" width="793" height="311"> </a> </div> <attachments> <attachment idref="CHEMCDX-00002" attachment-type="cdx" file="US06770748-20040803-C00002.CDX"> </attachment> <attachment idref="CHEMMOL-00002" attachment-type="mol" file="US06770748-20040803-C00002.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, and X and Y are identical or different, and each represent a hydrogen atom, an alkyl group, an alkenyl group, an alkinyl group, a cycloalkyl group, an aralkyl group, an aryl group, an acyl group, or a silyl group,</p>
    <p>or an amidite derivative thereof.</p>
    <p>The alkyl group represents a straight chain or branched chain alkyl group with 1 to 20 carbon atoms. Its examples include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl.</p>
    <p>The alkenyl group represents a straight chain or branched chain alkenyl group with 2 to 20 carbon atoms. Its examples include vinyl, allyl, butenyl, pentenyl, geranyl, and farnesyl.</p>
    <p>The alkinyl group represents a straight chain or branched chain alkinyl group with 2 to 20 carbon atoms. Its examples include ethynyl, propynyl, and butynyl.</p>
    <p>The cycloalkyl group represents a cycloalkyl group with 3 to 8 carbon atoms, and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Another example is a heterocyclic group in which one or more arbitrary methylene groups on the ring of the cycloalkyl group have been substituted by an oxygen atom, a sulfur atom, or an alkyl-substituted nitrogen atom. It is, for instance, a tetrahydropyranyl group.</p>
    <p>The aryl group refers to a monovalent substituent formed by removing one hydrogen atom from an aromatic heterocyclic group or an aromatic hydrocarbon group. Preferably, it represents a monovalent substituent formed by removing one hydrogen atom from an aromatic hydrocarbon group, and includes, for example, phenyl, tolyl, xylyl, biphenyl, naphthyl, anthryl, and phenanthryl. The carbon atom on the ring of the aryl group may be substituted by one or more of a halogen atom, a lower alkyl group, a hydroxyl group, an alkoxyl group, an amino group, a nitro group, and a trifluoromethyl group. The substituent in this case is, for example, a halogen atom, a hydroxyl group, an amino group, an alkoxy group, or an aryloxy group.</p>
    <p>The aralkyl group refers to an alkyl group bonded to an aryl group, and may be substituted. The aralkyl group that may be substituted represents an alkyl group bonded to an aryl group, with one or more arbitrary hydrogen atoms of the aryl group and the alkyl group being optionally substituted by the following substituents: Examples of the substituents are acyl, amino, aryl, alkyl, cycloalkyl, alkoxy, hydroxyl, nitro, and halogen.</p>
    <p>The amino group need not be substituted, but the amino group when substituted includes, for example, alkylamino, arylamino, and acylamino. Examples of the alkoxy group are methoxy, ethoxy, n-propoxy, 1-propoxy, n-butoxy, 1-butoxy, s-butoxy, t-butoxy, pentyloxy, hexyloxy, and phenoxy. Examples of the halogen atom are fluorine, chlorine, bromine, and iodine.</p>
    <p>The preferred examples of the aralkyl group are trityl, benzyl, phenethyl, tritylmethyl, diphenylmethyl, naphthylmethyl, and 4,4′-dimethoxytrityl (DMTr). Particularly preferred is a DMTr group.</p>
    <p>As the acyl group, acetyl, formyl, propionyl, benzoyl, and benzyloxycarbonyl can be exemplified. An example of the silyl group is a trialkylsilyl group, preferably trimethylsilyl, triethylsilyl, triisopropylsilyl, t-butyldimethylsilyl or t-butyldiphenylsilyl, and more preferably trimethylsilyl.</p>
    <p>The nucleotide analogue of the present invention is an oligonucleotide or polynucleotide analogue having one or more structures of the general formula (Ia) <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00003.png"> <img id="EMI-C00003" file="US06770748-20040803-C00003.TIF" wi="198.25155" he="75.1275" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00003" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00003.png" class="patent-full-image" width="793" height="300"> </a> </div> <attachments> <attachment idref="CHEMCDX-00003" attachment-type="cdx" file="US06770748-20040803-C00003.CDX"> </attachment> <attachment idref="CHEMMOL-00003" attachment-type="mol" file="US06770748-20040803-C00003.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>where B is a pyrimidine or purine nucleic acid base, or an analogue thereof,</p>
    <p>or an oligonucleotide or polynucleotide analogue of the general formula (II) <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00004.png"> <img id="EMI-C00004" file="US06770748-20040803-C00004.TIF" wi="214.8363" he="132.98985" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00004" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00004.png" class="patent-full-image" width="859" height="531"> </a> </div> <attachments> <attachment idref="CHEMCDX-00004" attachment-type="cdx" file="US06770748-20040803-C00004.CDX"> </attachment> <attachment idref="CHEMMOL-00004" attachment-type="mol" file="US06770748-20040803-C00004.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>where B<sup>1 </sup>and B are identical or different, and each represent a pyrimidine or purine nucleic acid base, or an analogue thereof, R is a hydrogen atom, a hydroxyl group, a halogen atom, or an alkoxy group, W<sup>1 </sup>and W<sup>2 </sup>are identical or different, and each represent a hydrogen atom, an alkyl group, an alkenyl group, an alkinyl group, a cycloalkyl group, an aralkyl group, an aryl group, an acyl group, a silyl group, a phosphoric acid residue, a naturally occurring nucleoside or a synthetic nucleoside bound via a phosphodiester bond, or an oligonucleotide or polynucleotide containing the nucleoside, n<sup>1</sup>'s or n<sup>2</sup>'s are identical or different, and each denote an integer of 0 to 50, provided that n<sup>1</sup>'s or n2's are not zero at the same time, and that not all of n<sup>2</sup>'s are zero at the same time, n<sup>3 </sup>denotes an integer of 1 to 50, provided that when n<sup>1 </sup>and/or n<sup>2 </sup>are or is 2 or more, B<sup>1 </sup>and B need not be identical, and R's need not be identical.</p>
    <p>The pyrimidine or purine nucleic acid base in the present invention refers to thymine uracil, cytosine, adenine, guanine, or derivatives thereof.</p>
    <p>An analogue of pyrimidine or purine nucleic acid base in the present invention includes any modified nucleic acid bases suitable for the purpose of the present invention. In particular, the analogue of pyrimidine or purine nucleic acid base useful in the present invention includes any modified nucleic acid base which can provide an oligonucleotide analogue suitable as an antisense oligonucleotide of the present invention when the modified nucleic acid base is introduced in the nucleotide analogues of the present invention as a nucleic acid base moiety.</p>
    <p>An analogue of pyrimidine or purine nucleic acid base which is useful in the present invention may be selected from the prior art or may be easily prepared by a person skilled in the art. Examples of the analogue of pyrimidine or purine nucleic acid base are described, for example, in the following references. However, it should not be construed that the analogue of the present invention is limited to those disclosed in the references.</p>
    <p>Incidentally, all of the references listed below are incorporated in the present application by reference.</p>
    <p>(1) I. Luyten and P. Herdewijin, Eur. J. Med. Chem. 33, 515-576 (1998)</p>
    <p>(2) Albert L. Lehninger et al. “Principles of Biochemistry” Second Edition, (1993) page 327, FIGS. 12-5</p>
    <p>(3) Stanley T. Crooke et al., “Antisense Research and Applications” (1993), page 277, FIG. <b>2</b> and page 282, FIG. 3</p>
    <p>(4) B. A. Schweitzer and E. T. Kool, J. Am. Chem. Soc., 117, 1863-1872 (1995)</p>
    <p>(5) S. O. Doronia et al., Chenm. Soc. Rev., (1997), 63-71</p>
    <p>(6) N. C. Chaudhuri, et al., Synlett, 1997, 341-347</p>
    <p>(7) T. E. Lehmann, et al., Chim. Acta, 80, 2002-2022 (1997)</p>
    <p>(8) C. A. Stein et al., Science, 261, 1004-1012 (1993)</p>
    <p>(9) E. Uhlmann et al., Chem. Rev., 90, 543-584 (1990)</p>
    <p>Some examples of modified pyrimidine and purine nucleic acid base are listed below. However, they are listed only for the purpose of showing examples and therefore should not be construed as limiting the present invention.</p>
    <p>(Examples of Modified pyrimidine or purine nucleic acid base) <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00005.png"> <img id="EMI-C00005" file="US06770748-20040803-C00005.TIF" wi="194.90625" he="672.32025" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00005" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00005.png" class="patent-full-image" width="779" height="2689"> </a> </div> <attachments> <attachment idref="CHEMCDX-00005" attachment-type="cdx" file="US06770748-20040803-C00005.CDX"> </attachment> <attachment idref="CHEMMOL-00005" attachment-type="mol" file="US06770748-20040803-C00005.MOL"> </attachment> </attachments> </chemistry> <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00006.png"> <img id="EMI-C00006" file="US06770748-20040803-C00006.TIF" wi="193.2336" he="617.60475" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00006" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00006.png" class="patent-full-image" width="772" height="2470"> </a> </div> <attachments> <attachment idref="CHEMCDX-00006" attachment-type="cdx" file="US06770748-20040803-C00006.CDX"> </attachment> <attachment idref="CHEMMOL-00006" attachment-type="mol" file="US06770748-20040803-C00006.MOL"> </attachment> </attachments> </chemistry> <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00007.png"> <img id="EMI-C00007" file="US06770748-20040803-C00007.TIF" wi="173.7855" he="684.79425" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00007" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00007.png" class="patent-full-image" width="695" height="2739"> </a> </div> <attachments> <attachment idref="CHEMCDX-00007" attachment-type="cdx" file="US06770748-20040803-C00007.CDX"> </attachment> <attachment idref="CHEMMOL-00007" attachment-type="mol" file="US06770748-20040803-C00007.MOL"> </attachment> </attachments> </chemistry> <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00008.png"> <img id="EMI-C00008" file="US06770748-20040803-C00008.TIF" wi="177.61275" he="575.1081" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00008" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00008.png" class="patent-full-image" width="710" height="2300"> </a> </div> <attachments> <attachment idref="CHEMCDX-00008" attachment-type="cdx" file="US06770748-20040803-C00008.CDX"> </attachment> <attachment idref="CHEMMOL-00008" attachment-type="mol" file="US06770748-20040803-C00008.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>The nucleoside analogue and nucleotide analogue of the present invention can be synthesized in the manner described below.</p>
    <p>In the following description, uracil is mainly used as a base, but other purine nucleic acid bases, pyrimidine nucleic acid bases and analogues thereof can also be used similarly. <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00009.png"> <img id="EMI-C00009" file="US06770748-20040803-C00009.TIF" wi="216.2538" he="417.4254" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00009" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00009.png" class="patent-full-image" width="865" height="1669"> </a> </div> <attachments> <attachment idref="CHEMCDX-00009" attachment-type="cdx" file="US06770748-20040803-C00009.CDX"> </attachment> <attachment idref="CHEMMOL-00009" attachment-type="mol" file="US06770748-20040803-C00009.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>Compound 1, synthesized from uridine in accordance with the literature [1) J. A. Secrist et al., J. Am. Chem. Soc., 101, 1554 (1979); 2) G. H. Jones et al., J. Org. Chem., 44, 1309 (1979)], was treated with tosyl chloride (TsCl) to tosylate only one of the two primary alcohols, leading to Compound 2. Compound 2 was acid hydrolyzed into a triol compound 3. Compound 3 was condensed with benzaldehyde in the presence of an acid catalyst to form a benzylidene compound 4. Compound 4 was reduced with sodium cyanoborohydride (NaBH<sub>3</sub>CN) in the presence of titanium tetrachloride (TiCl<sub>4</sub>) to obtain Compound 5. This compound was reacted with sodium hexamethyldisilazide (NaHMDS) in tetrahydrofuran (THF) to obtain a bicyclo compound 6 (Compound I: B=uracil (U), X=H, Y=benzyl). When Compound 6 was catalytically reduced in the presence of a palladium carbon catalyst, a diol compound 7 (Compound (I): B=U, X=Y=H) was obtained. Further treatment of Compound 7 with 4,4′-dimethoxytrityl chloride (DMTrCl) gave a trityl compound 8 (Compound I: B=U, X=DMTr, Y=H). Compounds 6, 7 and 8 can be used as starting materials for various compounds I.</p>
    <p>Compounds (I) having various nucleic acid bases, whether natural or nonnatural, other than uridine, can be synthesized by any of the following three methods:</p>
    <p>The first method is conversion from Compound 8. That is, Compound 8 is acetylated into Compound 9, and then reacted with 1,2,4-triazole to form Compound 10. Hydrolysis of this compound gave Compound 11 (Compound (I): B=cytosine (C), X=DMTr, Y=H). Compound 12 (Compound (I): B=benzoylcytosine (C<sup>Bz</sup>), X=DMTr, Y=H), which will become a starting material for oligonucleotide synthesis, can be easily obtained by benzoylation of Compound 11.<chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00010.png"> <img id="EMI-C00010" file="US06770748-20040803-C00010.TIF" wi="349.47045" he="173.30355" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00010" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00010.png" class="patent-full-image" width="1397" height="693"> </a> </div> <attachments> <attachment idref="CHEMCDX-00010" attachment-type="cdx" file="US06770748-20040803-C00010.CDX"> </attachment> <attachment idref="CHEMMOL-00010" attachment-type="mol" file="US06770748-20040803-C00010.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>The second method is a method performed via Compound 13 which can be easily obtained from D-ribose in accordance with the literature [3) A. G. M. Barrett et al., J. Org. Chem., 55, 3853 (1990); 4) G. H. Jones et al., ibid., 44, 1309 (1979)]. That is, Compound 13 was led to Compound 16 by three steps, and cyclized under basic conditions to obtain a desired methylglycosyl compound 17. The OMe group at the 1-position of this compound can be substituted by different natural nucleic acid bases or nonnatural nucleic acid base analogues by various methods which have already been developed. For example, a method as shown by a scheme ranging from Compound 17 to Compound 20 can be employed. <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00011.png"> <img id="EMI-C00011" file="US06770748-20040803-C00011.TIF" wi="216.027" he="637.05285" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00011" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00011.png" class="patent-full-image" width="864" height="2548"> </a> </div> <attachments> <attachment idref="CHEMCDX-00011" attachment-type="cdx" file="US06770748-20040803-C00011.CDX"> </attachment> <attachment idref="CHEMMOL-00011" attachment-type="mol" file="US06770748-20040803-C00011.MOL"> </attachment> </attachments> </chemistry> <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00012.png"> <img id="EMI-C00012" file="US06770748-20040803-C00012.TIF" wi="216.027" he="273.861" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00012" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00012.png" class="patent-full-image" width="864" height="1095"> </a> </div> <attachments> <attachment idref="CHEMCDX-00012" attachment-type="cdx" file="US06770748-20040803-C00012.CDX"> </attachment> <attachment idref="CHEMMOL-00012" attachment-type="mol" file="US06770748-20040803-C00012.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>The third method starts with diacetone D-glucose, which is obtained from D-glucose by one step and is commercially available. Compound 31 was prepared in accordance with a reference 5) R. D. Youssefyeh, J. P. H. Verheyden and J. G. Moffatt., J. Org. Chem., 44, 1301-1309 (1979). Then, Compound 31 was treated as shown by the following scheme to protect the two primary hydroxyl groups with a t-butyldiphenylsilyl group and a p-toluenesulfonyl group progressively. The protected compound was acetylated into Compound 34.<chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00013.png"> <img id="EMI-C00013" file="US06770748-20040803-C00013.TIF" wi="216.027" he="528.7842" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00013" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00013.png" class="patent-full-image" width="864" height="2115"> </a> </div> <attachments> <attachment idref="CHEMCDX-00013" attachment-type="cdx" file="US06770748-20040803-C00013.CDX"> </attachment> <attachment idref="CHEMMOL-00013" attachment-type="mol" file="US06770748-20040803-C00013.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>Compound 34 was condensed, separately, with thymine, benzoyladenine, and isobutyrylguanine activated upon trimethylsilylation (referred to as 2TMS·T, 2TMS·A<sup>Bz</sup>, and 3TMS·G<sup>iBu</sup>, respectively), to obtain Compounds 35, 40 and 44 in high yields, as indicated by the scheme offered below. Then, these condensates were subjected to deacetylation (Compounds 36, 41, 45), five-membered ring formation (Compounds 37, 42, 46), desilylation (Compounds 38, 43, 47), and further debenzylation to form desired compounds 39.<chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00014.png"> <img id="EMI-C00014" file="US06770748-20040803-C00014.TIF" wi="216.027" he="562.8609" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00014" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00014.png" class="patent-full-image" width="864" height="2251"> </a> </div> <attachments> <attachment idref="CHEMCDX-00014" attachment-type="cdx" file="US06770748-20040803-C00014.CDX"> </attachment> <attachment idref="CHEMMOL-00014" attachment-type="mol" file="US06770748-20040803-C00014.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>(2) Synthesis of Oligonucleotide Analogue</p>
    <p>Compound 8 is reacted with 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphoramidite to obtain an amidite compound 21. This compound is combined with a naturally occurring nucleoside amidite, and subjected to a DNA synthesizer to synthesize various oligonucleotide analogues. The synthesized crude products are purified using a reversed phase chromatographic column (Oligo-Pak). The purity of the purified product is analyzed by HPLC, whereby the formation of a purified oligonucleotide analogue can be confirmed. <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00015.png"> <img id="EMI-C00015" file="US06770748-20040803-C00015.TIF" wi="216.027" he="179.0586" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00015" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00015.png" class="patent-full-image" width="864" height="716"> </a> </div> <attachments> <attachment idref="CHEMCDX-00015" attachment-type="cdx" file="US06770748-20040803-C00015.CDX"> </attachment> <attachment idref="CHEMMOL-00015" attachment-type="mol" file="US06770748-20040803-C00015.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>At least one monomer unit as compound 8 can be contained in the oligonucleotide analogue. Alternatively, the monomer units may be present at two or more locations in the oligonucleotide analogue in such a manner as to be separated from each other via one or more naturally occurring nucleotides. The present invention makes it possible to synthesize an antisense molecule incorporating a necessary number of the nucleotide analogues (nucleoside analogues) of the invention (a necessary length of the nucleotide or nucleoside analogue) at a necessary location. The length of the entire oligonucleotide analogue is 2 to 50, preferably 10 to 30, nucleoside units.</p>
    <p>Such an oligonucleotide analogue (antisense molecule) is minimally degradable by various nucleases, and can be existent in vivo for a long time after administration. This antisense molecule functions, for example, to form a stable double helix together with a messenger RNA, thereby inhibiting the biosynthesis of a potentially pathogenic protein; or form a triple helix in combination with double-stranded DNA in a genome to inhibit transcription to messenger RNA. The oligonucleotide analogue can also suppress the proliferation of a virus which has infected.</p>
    <p>In light of these findings, an oligonucleotide analogue (antisense molecule) using the nucleoside analogue of the present invention is expected to be useful as drugs, including antineoplastics and antivirals, for treatment of diseases by inhibiting the actions of particular genes.</p>
    <p>The antisense molecule using the nucleotide (nucleoside) analogue of the present invention can be formulated into parenteral preparations or liposome preparations by incorporating customary auxiliaries such as buffers and/or stabilizers. As preparations for topical application, it may be blended with pharmaceutical carriers in common use to prepare ointments, creams, liquids or plasters.</p>
    <p>Synthesis of the nucleoside analogue and nucleotide analogue of the present invention will be described in more detail by way of the following Examples and Production Examples. In these Examples, uracil is mainly used as a base, but other purine nucleic acid bases, pyrimidine nucleic acid bases and analogues thereof can also be used similarly.</p>
    <heading>EXAMPLE 1</heading> <heading>Synthesis of Nucleoside Analogue</heading> <p>(1) Synthesis of 2′,3′-O-cyclohexylidene-4′-(p-toluenesulfonyloxymethyl)uridine (Compound 2)</p>
    <p>To an anhydrous pyridine solution (13.5 ml) of Compound 1 (956 mg, 2.70 mmols) known in the literature, p-toluenesulfonyl chloride (771 mg, 4.05 mmols) was added at room temperature in a stream of nitrogen, and the mixture was stirred for 5 hours at 60° C.</p>
    <p>To the reaction mixture, a saturated sodium bicarbonate solution was added, whereafter the reaction system was extracted with benzene 3 times. The organic phase was washed once with a saturated sodium chloride solution, and dried over anhydrous MgSO<sub>4</sub>. The solvents were distilled off under reduced pressure, and the residue was subjected to azeotropy with benzene 3 times. The resulting crude product was purified by silica gel column chromatography (CHCl<sub>3</sub>:MeOH=15:1), and then reprecipitated from benzene-hexane to obtain a white powder (Compound 2) (808 mg, 1.59 mmols, 59%).</p>
    <p>Compound 2: White powder, m.p. 104-106° C. (benzene-hexane). IR ν (KBr): 3326, 2929, 2850, 1628, 1577, 1544, 1437, 1311, 1244 cm<sup>−1</sup>. <sup>1</sup>H-NMR (d<sub>6</sub>-acetone): δ 1.45-1.67 (10H, m), 2.45 (3H, s), 3.71 (2H, ABq, J=12 Hz), 4.20 (2H, ABq, J=11 Hz), 4.92 (1H, d, J=6 Hz), 5.05, 5.06 (1H, dd, J=4.6 Hz), 5.60 (1H, d, J=7 Hz), 5.75 (1H, d, J=4 Hz), 7.48 (2H, d, J=8 Hz), 7.77 (1H, d, J=8 Hz), 7.81 (2H, d, J=8 Hz), 10.10 (1H, s,). <sup>13</sup>C-NMR (d<sub>6</sub>-acetone): δ21.5, 24.1, 24.5, 25.5, 34.8, 36.9, 63.5, 69.7, 82.5, 84.7, 87.8, 92.9, 102.9, 115.4, 128.8, 130.8, 133.9, 142.7, 145.9, 151.3, 163.5. Mass (EI): m/z 481 (M<sup>+</sup>−H<sub>2</sub>O).</p>
    <p>Anal. Calcd. for C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>9</sub>S·⅓ H<sub>2</sub>O: C, 53.69; H, 5.61; N, 5.44; S, 6.22. Found: C, 53.99;H, 5.48;N, 5.42;S, 6.10.</p>
    <p>(2) Synthesis of 4′-(p-toluenesulfonyloxymethyl)uridine (Compound 3)</p>
    <p>The above compound 2 (107 mg, 0.21 mmol) was stirred in TFA-H<sub>2</sub>O (98:2, 1 ml) for 10 minutes at room temperature. The reaction mixture was distilled off under reduced pressure, and EtOH was added to the residue, followed by performing azeotropy 3 times. The resulting crude product was purified by silica gel column chromatography (CHCl<sub>3</sub>:MeOH=10:1) to obtain Compound 3 (85.0 mg, 0.20 mmol, 94%).</p>
    <p>Compound 3: White powder, m.p. 119-120° C. IR ν (KBr): 3227, 3060, 2932, 2837, 1709, 1508, 1464, 1252, 978, 835, 763, 556 cm<sup>−1</sup>. <sup>1</sup>H-NMR (d<sub>6</sub>-acetone): δ 2.31 (3H, s), 2.84 (3H, s), 3.71 (2H, s), 4.13, 4.20 (2H, ABq, J=11 Hz), 4.28, 4.31 (1H, dd, J=9.6 Hz), 4.36 (1H, d, J=6 Hz), 5.54 (1H, d, J=8 Hz), 5.75 (1H, d, J=7 Hz), 7.32 (2H, d, J=8 Hz), 7.67 (2H, d, J=8 Hz), 7.70 (1H, d, J=8 Hz), 10.14 (1H, s). <sup>13</sup>C-NMR (d<sub>6</sub>-acetone): δ 21.5, 63.7, 70.8, 72.7, 74.6, 86.8, 88.8, 103.1, 128.8, 130.7, 133.9, 141.7, 145.8, 151.8, 163.9. Mass (EI): m/z 256 (M<sup>+</sup>-OTs).</p>
    <p>(3) Synthesis of 2′,3′-O-benzylidene-4′-(p-toluenesulfonyloxymethyl)uridine (Compound 4)</p>
    <p>In a stream of nitrogen, benzaldehyde (2.4 ml, excess) and zinc chloride (670 mg, 5.0 mmols) were added to the above compound 3 (400 mg, 0.93 mmols), and the mixture was stirred for 5 hours at room temperature. After the reaction was stopped by addition of a saturated sodium bicarbonate solution, the reaction mixture was extracted with chloroform, and washed with a saturated sodium bicarbonate solution, water, and a saturated sodium chloride solution. The organic phase was dried over anhydrous sodium sulfate. The solvents were distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (CHCl<sub>3</sub>:MeOH=40:1) to obtain Compound 4 (380 mg, 0.74 mmol, 80%).</p>
    <p>Compound 4: White powder. m.p. 99-102° C. (CH<sub>2</sub>Cl<sub>2</sub>-hexane). [α]<sub>D</sub> <sup>23</sup>-26.7° (c=1.0, CHCl<sub>3</sub>). IR ν (KBr): 3059, 1691, 1460, 1362, 1269, 1218, 1177 cm<sup>−1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>): δ 2.41 (3H, s), 3.25 (1H, br), 3.79 (2H, m), 4.19 (2H, s), 5.09 (1H, d, J=7 Hz), 5.28 (1H, dd, J=3.7 Hz), 5.60 (1H, d, J=4 Hz), 5.73 (1H, d, J=8 Hz), 5.94 (1H, s), 7.24 (1H, d, J=8 Hz), 7.38 (2H, d, J=9 Hz), 7.42 (5H, br), 7.69 (2H, d, J=9 Hz), 9.11 (1H, br). <sup>13</sup>C-NMR (CDCL<sub>3</sub>): δ 21.6, 63.5, 68.3, 77.2, 82.8, 84.2, 87.7, 94.9, 102.6, 107.5, 126.5, 127.9, 128.5, 129.7, 132.2, 135.0, 143.0, 145.0, 150.4, 163.5.</p>
    <p>Anal. Calcd. for C<sub>24</sub>H<sub>24</sub>N<sub>2</sub>O<sub>9</sub>S·⅓ H<sub>2</sub>O: C, 55.17; H, 4.76; N, 5.36; S, 6.14. Found: C, 55.19;H, 4.66;N, 5.29;S, 5.98.</p>
    <p>(4) Synthesis of 3′-O-benzyl-4′-(p-toluenesulfonyloxymethyl)uridine (Compound 5)</p>
    <p>To an acetonitrile solution (3 ml) of Compound 4 (150 mg, 0.29 mmol), sodium borocyanohydride (92 mg, 1.5 mmols) was added at room temperature in a stream of nitrogen. Then, titanium tetrachloride (0.16 ml, 1.5 mmols) was added dropwise under cooling with ice, and the mixture was stirred for 15 hours at room temperature. The reaction mixture was diluted with chloroform, and washed with a saturated sodium bicarbonate solution, water, and a saturated sodium chloride solution. Then, the organic phase was dried over anhydrous sodium sulfate. After the solvents were distilled off, the residue was purified by silica gel column chromatography (CHCl<sub>3</sub>:MeOH=25:1) to obtain Compound 5 (112 mg, 0.22 mmol, 75%).</p>
    <p>Compound 5: Colorless crystals. m.p. 195-197° C. (AcOEt-hexane). [α]<sub>D</sub> <sup>23</sup>-14.6° (c=1.0, CHCl<sub>3</sub>). IR ν (KBr): 3033, 2885, 2820, 1726, 1470, 1361, 1274, 1175, 1119 cm<sup>−1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 2.40 (3H, s), 3.59-3.77 (3H, m), 4.10, 4.24 (2H, AB, J=11 Hz), 4.32 (1H, d, J=6 Hz), 4.56 (2H, m), 4.69 (1H, d, J=11 Hz), 5.52 (1H, d, J=6 Hz), 5.67 (1H, d, J=8 Hz), 7.24-7.29 (7H, m), 7.48 (1H, d, J=8 Hz), 7.70 (2H, d, J=9 Hz), 9.91 (1H, s). <sup>13</sup>C-NMR (CDCl<sub>3</sub>): δ 21.6, 63.2, 69.2, 73.6, 74.6, 78.1, 86.6, 92.9, 102.5, 127.9, 128.2, 128.3, 128.6, 129.9, 132.3, 136.9, 142.4, 145.2, 150.7, 163.8.</p>
    <p>Anal. Calcd. for C<sub>24</sub>H<sub>26</sub>N<sub>2</sub>O<sub>9</sub>S: C, 55.59; H, 5.05; N, 5.40; S, 6.18. Found: C, 55.41;H, 5.02;N, 5.32;S, 6.15.</p>
    <p>(5) Synthesis of 3′—O-benzyl-2′-O, 4′-C-methyleneuridine (Compound 6)</p>
    <p>To an anhydrous THF solution (1.5 ml) of Compound 5 (80 mg, 0.16 mmol), an anhydrous benzene suspension (0.7 ml) of NaHMDS (3.2 mmols) was added at room temperature in a stream of nitrogen, and the mixture was stirred for 20 hours at room temperature. A saturated sodium bicarbonate solution was added to the reaction mixture, followed by extracting the mixture with CHCl<sub>3</sub>. The organic phase was washed with a saturated sodium chloride solution, and then dried over anhydrous sodium sulfate. After the solvents were distilled off under reduced pressure, the resulting crude product was purified by silica gel column chromatography (CHCl<sub>3</sub>:MeOH 10:1), and then recrystallized from MeOH to obtain Compound 6 (41 mg, 0.10 mmol, 61%).</p>
    <p>Compound 6: Colorless crystals. m.p. 217-219° C. (MeOH). [α]<sub>D</sub> <sup>23+</sup>108.4° (c=0.3, MeOH). IR ν (KBr): 3059, 2951, 1688, 1459, 1271, 1053 cm<sup>−1</sup>. <sup>1</sup>H-NMR (d<sub>6</sub>-DMSO) δ: 3.75, 3.85 (2H, AB, J=8 Hz), 3.77 (2H, d, J=5 Hz), 3.92 (1H, s), 4.44 (1H, s), 4.60 (2H, s), 5.39 (1H, t, J=5 Hz), 5.48 (1H, s), 7.31 (5H, m), 7.72 (1H, d, J=8 Hz), 11.37 (1H, s). <sup>13</sup>C-NMR (d<sub>6</sub>-DMSO) δ: 56.0, 71.1, 71.6, 75.8, 76.5, 86.5, 88.3, 100.9, 127.4, 127.6, 128.2, 137.9, 139.0, 150.0, 163.3. Mass (EI): m/z 346 (M<sup>+</sup>, 1.1).</p>
    <p>Anal. Calcd. for C<sub>17</sub>H<sub>18</sub>N<sub>2</sub>O<sub>6</sub>: C, 58.96; H, 5.24; N, 8.09. Found: C, 58.67;H, 5.23;N, 8.05.</p>
    <p>(6) Synthesis of 2′-O,4′-C-methyleneuridine (Compound 7)</p>
    <p>To a methanol solution (2.5 ml) of Compound 6 (25 mg, 0.072 mmol), 10% Pd-C (25 mg) was added, and the mixture was stirred for 15 hours at atmospheric pressure in a stream of hydrogen. The reaction mixture was filtered, and the solvent was distilled off. Then, the residue was purified by silica gel column chromatography (CHCl<sub>3</sub>:MeOH=10:1, then 5:1) to obtain Compound 7 (18.3 mg, quant.).</p>
    <p>Compound 7: Colorless crystals. m.p. 239-243° C. (MeOH). [α]<sub>D</sub> <sup>23</sup>+92.2° (c=0.3, MeOH). IR ν (KBr): 3331, 3091, 3059, 2961, 1689, 1463, 1272, 1049 cm<sup>−1</sup>. <sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ: 3.76, 3.96 (2H, AB, J=8 Hz), 3.90 (2H, s), 4.04 (1H, s), 4.28 (1H, s), 5.55 (1H, s), 5.69 (1H, d, J=8 Hz), 7.88 (1H, d, J=8 Hz).</p>
    <p>Anal. Calcd. for C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>O<sub>6</sub>: C, 46.88; H, 4.72; N, 10.93. Found: C, 46.74;H, 4.70;N, 10.84.</p>
    <p>(7) 5′-O-(4,4′-dimethoxytrityl)-2′-0,4′-C-methyleneuridine (Compound 8)</p>
    <p>To Compound 7 (140 mg, 0.53 mmol), anhydrous pyridine was added, followed by performing azeotropy of the mixture 3 times. Then, the product was converted into an anhydrous pyridine solution (1.5 ml), and 4,4′-dimethoxytrityl chloride (210 mg, 0.63 mmol) and DMAP (6.5 mg, 0.053 mmol) were added at room temperature in a stream of nitrogen. The mixture was stirred for 5 hours at room temperature. To the reaction mixture, a saturated sodium bicarbonate solution was added, followed by extraction with CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was washed with water and a saturated sodium chloride solution, and then dried over anhydrous sodium sulfate. After the solvents were distilled off under reduced pressure, the resulting crude product was purified by silica gel column chromatography (CHCl<sub>3</sub>:MeOH=40:1) to obtain Compound 8 (230 mg, 0.34 mmol, 66%).</p>
    <p>Compound 8: White powder. m.p. 117-120° C. (CHCl<sub>3</sub>). [α]<sub>D</sub> <sup>23</sup>+17.2° (c=1.0, CHCl<sub>3</sub>). IR ν (KBr): 3393, 3101, 2885, 1689, 1464, 1272, 1047 cm<sup>−1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 2.59 (1H, br), 3.56 (2H, q, J=7, 11 Hz), 3.87 (1H, d, J=7 Hz), 4.26 (1H, s), 4.47 (1H, s), 5.60 (1H, d, J=9 Hz), 5.63 (1H, s), 5.84 (4H, d, J=9 Hz), 7.22-7.45 (9H, m), 7.93 (1H, d, J=9 Hz).</p>
    <heading>EXAMPLE 2</heading> <heading>Synthesis of Nucleoside Analogue</heading> <p>(1) Synthesis of methyl=-5-O-(t-butyldiphenylsilyl)-4-hydroxymethyl-2,3-O-isopropylidene-β-D-ribofuranoside (Compound 14)</p>
    <p>In a stream of nitrogen, Et<sub>3</sub>N (2.62 ml, 18.8 mmols) and t-butyldiphenylsilyl chloride (4.88 ml, 18.8 mmols) were added to an anhydrous CH<sub>2</sub>Cl<sub>2 </sub>solution (40 ml) of Compound 13 (2.00 g, 8.54 mmols) known in the literature under cooling with ice, and the mixture was stirred for 13 hours at room temperature. To the reaction mixture, a saturated sodium bicarbonate solution was added, whereafter the reaction system was extracted with AcOEt 3 times. The organic phase was washed once with a saturated sodium chloride solution, and then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane:AcOEt=5:1) to obtain colorless oily matter (Compound 14) (2.82 g, 5.98 mmols, 70%).</p>
    <p>[α]<sub>D</sub> <sup>17</sup>−16.2° (c=0.52, CHCl<sub>3</sub>). IR ν (KBr): 3510, 3061, 2938, 2852, 1465, 1103 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 1.09 (9H, s), 1.28 (3H, s), 1.49 (3H, s), 3.22 (3H, s), 3.67, 3.76 (2H, AB, J=11 Hz), 3.88, 3.93 (2H, AB, J=11 Hz), 4.49 (1H, d, J=6 Hz), 4.57 (1H, d, J=6 Hz), 4.93 (1H, s), 7.38-7.43 (6H, m), 7.67 (4H, d, J=7 Hz).</p>
    <p> <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ: 19.2, 24.4, 25.9, 26.9, 55.0, 62.9, 64.8, 82.2, 85.9, 88.7, 108.6, 112.6, 127.8, 129.9, 133.0, 135.7.</p>
    <p>Anal. Calcd. for C<sub>26</sub>H<sub>36</sub>O<sub>6</sub>Si·¼ H<sub>2</sub>O: C, 65.45; H, 7.71. Found: C, 65.43; H, 7.59.</p>
    <p>(2) Synthesis of methyl=-5-O-(t-butyldiphenylsilyl-2,3-O-isopropylidene-4-(p-toluenesulfonyloxymethyl)-β-ribofuranoside (Compound 15)</p>
    <p>In a stream of nitrogen, Et<sub>3</sub>N (3.92 g, 28.0 mmols), p-toluenesulfonyl chloride (1.34 g, 7.22 mmols), and 4-dimethylaminopyridine (90 mg, 0.72 mmol) were added to an anhydrous CH<sub>2</sub>Cl<sub>2 </sub>solution (15 ml) of Compound 14 (2.13 g, 4.51 mmols), and the mixture was stirred for 17 hours at room temperature. To the reaction mixture, a saturated sodium bicarbonate solution was added, whereafter the reaction system was extracted with AcOEt 3 times. The organic phase was washed once with a saturated sodium chloride solution, and then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane:AcOEt=10:1) to obtain colorless oily matter, Compound 15 (2.76 g, 4.42 mmols, 98%). [α]<sub>D</sub> <sup>17</sup>−3.82° (c=0.56, CHCl<sub>3</sub>). IR ν (KBr): 2934, 2852, 1369, 1104 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 1.02 (9H, s), 1.20 (3H, s), 1.32 (3H, s), 2.41 (3H, s), 3.09 (3H, s), 3.51, 3.77 (2H, AB, J=10 Hz), 4.34 (1H, d, J=6 Hz), 4.25, 4.39 (2H, AB, J=9 Hz), 4.47 (1H, d, J=6 Hz), 4.77 (1H, s), 7.28, 7.81 (4H, AB, J=9 Hz), 7.39-7.44 (6H, m), 7.62-7.65 (4H, m), 7.81 (2H, d, J=9 Hz).</p>
    <p> <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ: 19.2, 21.6, 24.5, 25.8, 26.8, 54.9, 62.7, 68.8, 81.9, 85.6, 87.5, 108.7, 112.8, 127.7, 127.8, 128.2, 129.6, 129.9, 132.9, 135.6, 144.4.</p>
    <p>Anal. Calcd. for C<sub>33</sub>H<sub>42</sub>O<sub>8</sub>SSi: C, 63.23; H, 6.75; S, 5.11. Found: C, 62.99; H, 6.53; S, 5.13.</p>
    <p>(3) Synthesis of methyl=-5-O-(t-butyldiphenylsilyl)-4-(p-toluenesulfonyloxymethyl)-β-D-ribofuranoside (Compound 16)</p>
    <p>Trifluoroacetic acid (14 ml) was added to a THF-H<sub>2</sub>O [11 ml, 8:3 (v/v)] solution of Compound 15 (645 mg, 1.03 mmols) at room temperature, and the mixture was stirred for 20 minutes at room temperature. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane:AcOEt=5:1) to obtain colorless oily matter, Compound 16 (464 mg, 0.79 mmol, 77%). [α]<sub>D</sub> <sup>17</sup>−35.8° (c=1.90,CHCl<sub>3</sub>) IR ν (KBr):3499, 3051, 2931, 2840, 1594, 1468, 1362, 1109 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 1.02(9H, s), 2.42(3H, s), 3.16(3H, s), 3.54, 3.70(2H, AB, J=10 Hz), 3.97(1H, d, J=5 Hz), 4.18(1H, d, J=5 Hz), 4.26, 4.39(2H, AB, J=10 Hz), 4.73(1H, s), 7.30(2H, d, J=8 Hz), 7.36-7.44 (6H, m), 7.59-7.66(4H, m),7.78(2H, d, J=8 Hz). <sup>13</sup>C-NMR (CDCl<sub>3</sub>) bc 19.2, 21.6, 26.7, 55.2, 66.5, 69.6, 74.0, 75.2, 76.5, 84.8, 107.5, 127.7, 128.0, 129.8, 132.6, 132.7, 132.8, 135.5, 135.6, 144.9.</p>
    <p>Anal. Calcd for C<sub>30</sub>H<sub>38</sub>SSiO<sub>8</sub>·¼ H<sub>2</sub>O:C, 60.94; H, 6.56. Found:C, 60.94; H, 6.43.</p>
    <p>(4) Synthesis of methyl=-5-O-(t-butyldiphenylsilyl)-2-O,4-C-methylene-β-D-ribofuranoside (Compound 17) and methyl=-5-O-(t-butyldiphenylsilyl)-3-O, 4-C-methylene-β-D-ribofuranoside (Compound 18)</p>
    <p>In a stream of nitrogen, a benzene suspension (1.6 ml) of NaHMDS (3.30 mmols) was added to an anhydrous THF solution (4 ml) of Compound 16 (194 mg, 0.33 mmol) at room temperature, and the mixture was stirred for 1 hour at room temperature. After a saturated sodium bicarbonate solution was added to the reaction mixture, the reaction solvents were distilled off, and the residue was extracted with AcOEt 3 times. The organic phase was washed once with a saturated sodium chloride solution, and then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane:AcOEt=5:1) to obtain colorless oily matter, Compound 17 (48 mg, 0.116 mmol, 35%) and colorless oily matter, Compound 18 (59 mg, 0.142 mmol, 43%).</p>
    <p>Compound 17: IR ν (KBr):3438, 3064, 1103, 1036 cm<sup>−1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 1.08(9H, s), 2.04(1H, br s), 3.39(3H, s), 3.65, 3.98(2H, AB, J=8 Hz), 3.95, 4.02(2H, AB, J=12 Hz), 4.02(1H, s), 4.30 (1H, s), 4.79(1H, s), 7.38-7.46(6H, m), 7.65-7.69(4H, m).</p>
    <p> <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ<sub>c</sub>: 19.2, 26.7, 55.0, 60.7, 71.2, 73.1, 79.9, 8 5.5, 104.3, 127.8, 129.9, 130.0, 132.9, 135.6, 135.7.</p>
    <p>Anal. Calcd for C<sub>23</sub>H<sub>30</sub>O<sub>5</sub>Si·¼ H<sub>2</sub>O:C, 65.68; H, 7.34. Found:C, 65.9 8; H, 7.23.</p>
    <p>Compound 18: IR ν (KBr):3456, 3058, 2938, 2852, 1467, 1108 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 1.10(9H, s), 3.26(3H, s), 3.71(2H, s), 4.02(1H, d, J=6 Hz), 4.35, 4.95(2H, d, J=7 Hz), 5.01(1H, s), 5.11(1H, d, J=6H z), 7.38-7.44(6H, m), 7.66(4H, d, J=7 Hz).</p>
    <p> <sup>13</sup>C-NMR(CDCl<sub>3</sub>) δ: 19.3, 26.8, 55.4, 63.7, 75.1, 77.9, 84.5, 86.3, 111.9, 127.8, 128.0, 129.9, 132.9, 133.0, 135.6, 135.8, 135.9.</p>
    <p>Anal.Calcd for C<sub>23</sub>H<sub>30</sub>O<sub>5</sub>Si·1¼H<sub>2</sub>O:C, 65.91; H, 7.34. Found:C, 66.07; H, 7.14.</p>
    <p>(5) Synthesis of methyl=-3-O,acetyl-5-O-(t-butyldiphenylsilyl)-2-O,4-C-methylene-β-D-ribofuranoside (Compound 19)</p>
    <p>In a stream of nitrogen, acetic anhydride (0.38 ml, 4.08 mmols) and 4-dimethylaminopyridine (21 mg, 0.170 mmols) were added to an anhydrous pyridine solution (10 ml) of Compound 17 (704 mg, 1.70 mmols) at room temperature, and the mixture was stirred for 3 hours at room temperature. After a saturated sodium bicarbonate solution was added to the reaction mixture, the system was extracted with AcOEt 3 times. The organic phase was washed once with a saturated sodium chloride solution, and then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane:AcOEt=7:1) to obtain colorless oily matter, Compound 19 (665 mg, 1.46 mmols, 86%).</p>
    <p>[α]<sub>D</sub> <sup>17</sup>−34.3° (c=0.93,CHCl<sub>3</sub>) IR ν (KBr):3438, 3064, 2934, 1749, 1468, 1103, 1036 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 0.99(9H, s), 1.97(3H, s), 3.34(3H, s), 3.69, 3.86(2H, AB, J=8 Hz), 3.86(2H, s), 4.17(1H, s), 4.77(1H, s), 5.06 (1H, s), 7.28-7.39(6H, m), 7.58-7.63(4H, m).</p>
    <p> <sup>13</sup>C-NMR(CDCl<sub>3</sub>) δ<sub>c</sub>: 19.3, 20.9, 26.7, 55.0, 60.3, 72.0, 73.6, 78.3, 85.3, 104.4, 127.7, 129.8, 133.0, 135.6, 169.8.</p>
    <p>Anal.Calcd for C<sub>25</sub>H<sub>32</sub>O<sub>6</sub>Si·¼ H<sub>2</sub>O:C,65.12; H,7.10. Found:C, 65.27;H,7.00.</p>
    <p>(6) Synthesis of 5′-O-(t-butyldiphenylsilyl)-2′-O,4′-C-methylene-5-methyluridine (Compound 20)</p>
    <p>In a stream of nitrogen, O,O′-bistrimethylsilylthymine (154 mg, 0.598 mmols) was added to an anhydrous CH<sub>3</sub>CN solution (2 ml) of Compound 19 (109.2 g, 0.239 mmol) at room temperature. Then, a 1,1-dichloroethane (0.31 ml) solution of trimethylsilyltrifluoromethane sulfonate (0.82 ml, 8.74 mmols) was added under cooling with ice, and the mixture was stirred for 18 hours at room temperature. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and a saturated sodium bicarbonate solution was added, followed by extracting the system with AcOEt 3 times. The organic phase was washed once with a saturated sodium chloride solution, and then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (hexane:AcOEt=3:1) to obtain colorless oily matter, Compound 20 (87.7 mg, 0.173 mmol, 70%).</p>
    <p>IR ν (KBr):3048, 2935, 2852, 1749, 1466, 1369, 1234, 1108, 1040 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 1.06(9H, s), 1.94(3H, s), 2.98(1H, br s), 3.63, 4.00(2H, AB, J=10Hz), 3.72(1H, d, J=7 Hz), 3.82-3.84(2H, m), 4.30 (1H, s), 5.25(1H, s), 7.40-7.46(6H, m), 7.60(4H, d, J=6 Hz), 7.66 (1H, s), 9.68(1H, br s).</p>
    <heading>EXAMPLE 3</heading> <heading>Synthesis of Nucleoside Analogue (Different Method)</heading> <p>(1) Synthesis of 3-O-benzyl-5-O-t-butyldiphenylsilyl-4-(hydroxymethyl)-1,2-O-isopropylidene-α-D-erythropentofuranose (Compound 32)</p>
    <p>In a stream of nitrogen, triethylamine (3.71 ml, 26.6 mmols) and t-butyldiphenylsilyl chloride (6.94 ml, 26.7 mmols) were added, under cooling with ice, to a methylene chloride solution (50 ml) of Compound 31 (2.50 g, 8.08 mmols) prepared in accordance with the aforementioned reference 5). The mixture was stirred for 10.5 hours at room temperature. After a saturated sodium bicarbonate solution was added to the reaction mixture, the system was extracted with ethyl acetate. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane:=1:4→1:3) to obtain a white solid, Compound 32 (2.97 g, 5.41 mmols, 67%).</p>
    <p>m.p. 98-99° C. (hexane). [α]<sub>D</sub> <sup>20</sup>+54.8° (c=1.12, acetone).</p>
    <p>IR ν max (KBr): 3553, 2936, 1463, 1379, 1107 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ: 1.13 (9H, s), 1.50 (3H, s), 1.78 (3H, s), 2.56 (1H, t, J=7 Hz), 3.82, 3.92 (2H, AB, J=11 Hz), 3.94 (2H, t, J=6 Hz), 4.57 (1H, d, J=5 Hz), 4.64, 4.95 (2H, AB, J=12 Hz), 4.83 (1H, dd, J=4, 5 Hz), 5.95 (1H, d, J=4 Hz), 7.44-7.55 (11H, m), 7.72-7.78 (4H, m). <sup>13</sup>C-NMR(CDCl<sub>3</sub>) δ<sub>c</sub>: 19.2, 26.2, 26.5, 26.8, 63.2, 65.4, 72.5, 77.9, 79.1, 87.4, 104.4, 113.7, 127.6, 127.7, 128.0, 128.5, 129.5, 129.7, 132.9, 133.1, 134.7, 135.5, 137.2.</p>
    <p>Anal. Calcd for C<sub>32</sub>H<sub>40</sub>O<sub>6</sub>Si: C, 70.04; H, 7.38. Found: C, 70.19; H, 7.35.</p>
    <p>(2) Synthesis of 3-O-benzyl-5-O-(t-butyldiphenylsilyl)-4-(p-toluenesulfonyloxymethyl)-1,2-α-D-erythropentofuranose (Compound 33)</p>
    <p>In a stream of nitrogen, triethylamine (395 μl, 2.83 mmols), p-toluenesulfonyl chloride (139.2 mg, 0.730 mmol), and 4-dimethylaminopyridine (8.92 mg, 0.0730 mmols) were added, under cooling with ice, to a methylene chloride solution of Compound 32 (250 mg, 0.456 mmol). The mixture was stirred for 15.5 hours at room temperature. After a saturated sodium bicarbonate solution was added to the reaction mixture, the system was extracted with ethyl acetate. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane:=1:6) to obtain light yellow oily matter, Compound 33 (310.6 mg, 0.442 mmol, 97%).</p>
    <p>[α]<sub>D</sub> <sup>20</sup>+16.0° (c=0.44, acetone). IR ν max (KBr): 2935, 1595, 1462, 1363, 1174, 1106 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ: 1.08 (9H, s), 1.40 (3H, s), 1.46 (3H, s), 2.48 (3H, s), 3.68, 3.83 (2H, AB, J=11 Hz), 4.45 (2H, dd, J=4, 5 Hz), 4.64, 4.81 (2H, AB, J=12 Hz), 4.68 (1H, dd, J=4, 5 Hz), 5.81 (1H, d, J=4 Hz), 7.32 (2H, d, J=8 Hz), 7.42-7.72 (15H, m), 7.82, (2H, d, J=8 Hz), 7.66 (4H, m), 7.72 (2H, d, J=8 Hz).</p>
    <p> <sup>13</sup>C-NMR(CDCl<sub>3</sub>) δ<sub>c</sub>: 19.1, 21.5, 26.1, 26.4, 26.7, 64.4, 70.0, 72.5, 78.1, 78.9, 85.4, 104.2, 113.6, 127.3, 127.7, 127.9, 128.0, 128.4, 129.6, 129.7, 129.8, 132.7, 132.8, 135.5, 137.2, 144.4. MS(EI) m/z: 646 (M<sup>+</sup>-t-Bu). High-MS(EI):</p>
    <p>Calcd for C<sub>35</sub>,H<sub>37</sub>O<sub>8</sub>SSi (M<sup>+</sup>-t-Bu) 645.1978, Found: 645.1969.</p>
    <p>(3) Synthesis of 1,2-di-O-acetyl-3-O-benzyl-5-O-t-butyldiphenylsilyl-4-(p-toluenesulfonyloxymethyl)-α- and -β-D-ribofuranose (Compound 34)</p>
    <p>In a stream of nitrogen, acetic anhydride (6.0 ml, 63.6 mmols) and concentrated sulfuric acid (56 μl, 1.10 μmol) were added to an acetic acid solution (56 ml) of Compound 34 (3.70 g, 5.27 mmols). The mixture was stirred for 2 hours at room temperature. The reaction mixture was emptied into iced water (300 ml), and stirred for 30 minutes. After a saturated sodium chloride solution was added, the mixture was extracted with ethyl acetate. Then, the organic phase was dried over magnesium sulfate. The solvents were distilled off, and the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane, 2:1) to obtain yellow oily matter, Compound 34 (3.36 g, 4.53 mmols, 86%), as an α-β (1:4) mixture.</p>
    <p>IR ν max (KBr): 2934, 2863, 1751, 1365, 1217, 1106 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) [β-configuration] δ: 1.02 (9H, s), 1.77 (3H, s), 1.98 (3H, s), 2.39 (3H, s), 3.61, 3.76 (2H, AB, J=11 Hz), 4.21-4.58 (5H, m), 5.26 (1H, d, J=5 Hz), 5.94 (1H, s), 7.15-7.59 (13H, m), 7.58-7.66 (4H, m), 7.72 (2H, d, J=8 Hz). [α-configuration] d: 1.02 (9H, s), 1.98 (3H, s), 2.36 (3H, s), 3.48, 3.58 (2H, AB, J=11 Hz), 4.21-4.58 (5H, m), 5.12 (1H, dd, J=5, 6 Hz), 6.33 (1H, d, J=5 Hz), 7.15-7.59 (13H, m), 7.58-7.66 (4H, m), 7.72 (2H, d, J=8 Hz).</p>
    <p> <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ<sub>c</sub>: 14.2, 19.3, 20.5, 20.8, 21.6, 26.7, 26.8, 60.3, 64.8, 69.1, 73.6, 74.1, 78.6, 85.3, 97.4, 127.4, 127.6, 127.7, 127.8, 127.9, 128.0, 128.2, 128.3, 128.4, 129.5, 129.6, 1289.8, 129.9, 132.4, 132.8, 132.9, 135.4, 135.5, 135.6, 136.9, 144.5, 168.7, 169.4. High-MS(FAB): Calcd for C<sub>40</sub>H<sub>46</sub>N<sub>2</sub>O<sub>10</sub>SSiNa (M<sup>+</sup>+Na): 769.2479, Found 769.2484.</p>
    <p>(4) Synthesis of 2′-O-acetyl-3′-O-benzyl-5′-O-t-butyldiphenylsilyl-4′-p-toluenesulfonyloxymethyl-5-methyluridine (Compound 35)</p>
    <p>In a stream of nitrogen, 2TMS-T (1.04 g, 4.03 mmols) and trimethylsilyltrifluoromethane sulfonate (730 μl, 4.03 mmols) were added, under cooling with ice, to a 1,2-dichloroethane solution (26 ml) of Compound 34 (1.88 g, 2.52 mmols), and the mixture was stirred for 17 hours at room temperature. A saturated sodium bicarbonate solution was added to the reaction mixture, and the system was filtered through Celite, followed by extracting the mother liquor with chloroform. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane, 2:3) to obtain a white powder, Compound 35 (2.00 g, 2.44 mmols, 97%).</p>
    <p>m.p. 70-71.5° C. [α]<sub>D</sub> <sup>24</sup>+4.58° (c=1.25, acetone).</p>
    <p>IR ν max (KBr): 3059, 2934, 1694, 1465, 1368, 704 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ: 1.18 (9H, s), 1.63 (3H, d, J=1 Hz), 2.10 (3H, s), 2.42 (3H, s), 3.73, 3.86 (2H, AB, J=11 Hz), 4.12, 4.20 (2H, AB, J=11 Hz), 4.44, 4.57 (2H, AB, J=11 Hz), 4.45 (1H, d, J=6 Hz), 5.38 (1H, t, J=6 Hz), 6.02 (1H, d, J=6 Hz), 7.21-7.60 (13H, m), 7.62-7.69 (7H, m), 8.91 (1H, br s).</p>
    <p> <sup>13</sup>C-NMR(CDCl<sub>3</sub>) δ<sub>c</sub>: 11.9, 19.3, 20.6, 21.6, 27.0, 65.3, 68.6, 74.1, 74.8, 77.2, 77.3, 86.0, 86.4, 111.6, 127.9, 128.0, 128.2, 128.5, 129.7, 130.1, 130.2, 131.8, 132.3, 132.5, 135.3, 135.5, 135.6, 136.8, 144.9, 150.2, 163.4, 170.2. MS (FAB) m/z: 813 (M<sup>+</sup>+H).</p>
    <p>Anal. Calcd for C<sub>43</sub>H<sub>48</sub>N<sub>2</sub>O<sub>10</sub>SSi·2H<sub>2</sub>O: C, 60.83; H, 6.17; N, 3.30. Found: C, 60.55; H, 5.78; N, 3.22.</p>
    <p>(5) Synthesis of 3′-O-benzyl-5′-O-t-butyldiphenylsilyl-4′-p-toluenesulfonyloxymethyl-5-methyluridine (Compound 36)</p>
    <p>Potassium carbonate (12.75 mg, 0.0923 mmol) and water (0.5 ml) were added, under cooling with ice, to a methyl alcohol solution (4 ml) of Compound 35 (250 mg, 0.308 mmol), and the mixture was stirred for 22 hours at room temperature. Under cooling with ice, acetic acid was added to the reaction mixture to neutralize it, whereafter the solvent was distilled off under reduced pressure. After water was added to the residue, the mixture was extracted with ethyl acetate. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvent was distilled off under reduced pressure, and then the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane, 3:2) to obtain a white powder, Compound 36 (216.7 mg, 0.283 mmol, 92%). mp. 74-77° C. [α]<sub>D</sub> <sup>23</sup>+5.15° (c=1.23, CHCl<sub>3</sub>). IR ν max (KBr) 3048, 2934, 1695, 1363, 1181, 1108, 977, 819, 704 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) d: 1.05 (9H, s), 1.65 (3H, d, J=1 Hz), 2.39 (3H, s), 3.04 (1H, br d, J=9 Hz), 3.72 (2H, s), 4.17 (2H, s), 4.18 (1H, d, J=5 Hz), 4.24-4.32 (1H, m), 4.54, 4.62 (2H, AB, J=11 Hz), 5.62 (1H, d, J=6 Hz), 7.19-7.69 (20H, m), 8.46 (1H, br s).</p>
    <p> <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ<sub>c</sub>: 12.1, 19.4, 26.9, 58.8, 72.0, 72.2, 75.8, 76.7, 87.4, 88.8, 110.4, 127.7, 12.79, 128.1, 128.2, 128.5, 128.7, 129.8, 130.0, 130.1, 132.2, 134.3, 135.3, 135.5, 136.8, 149.8, 163.9. MS(FAB) m/z: 771 (M<sup>+</sup>+H).</p>
    <p>Anal. Calcd for C<sub>41</sub>H<sub>46</sub>N<sub>2</sub>O<sub>9</sub>SSi: C, 63.41; H, 6.16; N, 3.51; S, 3.95.</p>
    <p>Found: C, 63.87; H, 6.01; N, 3.63; S, 4.16.</p>
    <p>(6) Synthesis of 3′-O-benzyl-5′-O-t-butyldiphenylsilyl-2′-0,4′-C-methylene-5-methyluridine (Compound 37)</p>
    <p>In a stream of nitrogen, sodium bis(trimethylsilyl)amide (1.0 M in THF, 8.47 ml, 8.47 mmols) was added, under cooling with ice, to a tetrahydrofuran solution (30 ml) of Compound 36 (1.86 g, 2.42 mmols), and the mixture was stirred for 1 hour at room temperature. A saturated sodium bicarbonate solution (14 ml) was added to the reaction mixture, and then the solvent was distilled off under reduced pressure. After water was added to the residue, the mixture was extracted with chloroform. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane, 2:3) to obtain a white powder, Compound 37 (1.42 g, 2.37 mmols, 98%).</p>
    <p>m.p. 70.5-72° C. [α]<sub>D</sub> <sup>22</sup>+52.47° (c=1.025, acetone). IR ν max (KB r): 2936, 1694, 1465, 1275, 1106, 1055, 809, 704 cm<sup>−1</sup>.</p>
    <p>1H-NMR(CDCl<sub>3</sub>) δ: 1.21 (9H, s), 1.76 (3H, s), 3.88, 4.07(2H, AB, J=8 Hz), 4.07, 4.15 (2H, AB, J=11 Hz), 4.16 (1H, s), 4.66, 4.80 (2H, AB, J=11 Hz), 4.76 (1H, s), 7.34-7.79 (16H, m), 10.0 (1H, br s). MS (FAB) m/z: 599 (M<sup>+</sup>+H).</p>
    <p>Anal. Calcd for C<sub>34</sub>H<sub>38</sub>N<sub>2</sub>O<sub>6</sub>Si·2H<sub>2</sub>O: C, 64.33; H, 6.03; N, 4.41. Found: C, 64.58; H, 6.15; N, 4.28.</p>
    <p>(7) Synthesis of 3′-O-benzyl-2′-O,4′-C-methylene-5-methyluridine (Compound 38)</p>
    <p>In a stream of nitrogen, tetrabutylammonium fluoride (1.0 M in THF, 379 μl, 0.379 μmol) was added to a tetrahydrofuran solution (1 ml) of Compound 37 (188.7 mg, 0.316 mmol), and the mixture was stirred for 2.5 hours at room temperature. The reaction mixture was distilled under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOEt-hexane, 1:1-1:0) to obtain a white powder, Compound 38 (94.6 mg, 0.262 mmol, 83%).</p>
    <p>IR ν max (KBr): 3424, 3183, 3063, 2950, 1691, 1463, 1273, 1057, 734 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 1.90(3H, d, J=1 Hz), 3.83, 4.05(2H, AB, J=8 Hz), 3.93, 4.02(2H, AB, J=12 Hz), 3.94(1H, s), 4.53(1H, s), 4.56, 4.58(2H, AB, J=12 Hz), 5.65 (1H, s), 7.32(5H, s), 7.44(1H, d, J=1 Hz). High-MS (EI):</p>
    <p>Calcd for C<sub>18</sub>H<sub>20</sub>NO<sub>6 </sub>(M<sup>+</sup>): 360.1321, Found: 360.1312.</p>
    <p>(8) Synthesis of 2′-O,4′-C-methylene-5-methyluridine (Compound 39a)</p>
    <p>To a methyl alcohol solution (4 ml) of Compound 38 (86.5 mg, 0.240 mmol), 20% Pd(OH)<sub>2</sub>-C (86.5 mg) was added, and the mixture was stirred for 14.5 hours at atmospheric pressure in a stream of hydrogen. The reaction mixture was filtered, and then the solvent was distilled off under reduced pressure to obtain colorless crystals, Compound 39 (62.5 mg, 0.230 mmol, 96%).</p>
    <p>mp. 194-195° C. [α]<sub>D</sub> <sup>20</sup>+53.7° (c=1.02, EtOH). IR ν max (KBr): 3323, 3163, 3027, 2889, 2826, 1689, 1471, 1276, 1057 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ: 1.89 (3H, q, J=1 Hz), 3.74, 3.95 (2H, AB, J=8 Hz), 3.90 (1H, s), 4.07 (1H, s), 4.26 (1H, s), 5.53 (1H, s), 7.74 (1H, d, J=1 Hz).</p>
    <p> <sup>13</sup>C-NMR (CD<sub>3</sub>OD) δ<sub>c</sub>: 12.6, 57.6, 70.3, 72.4, 80.8, 88.3, 90.4, 110.7, 136.8, 151.8, 166.5.</p>
    <heading>EXAMPLE 4</heading> <p>(1) Synthesis of 2′-O-acetyl-3′-O-benzyl-5′O-t-butyldiphenylsilyl-4′-p-toluenesulfonyloxymethyl-N<sup>6</sup>-benzoyladenosine (Compound 40)</p>
    <p>In a stream of nitrogen, a 1,2-dichloroethane solution (5.0 ml) of Compound 34 (250 mg, 0.336 mmol) and trimethylsilyltrifluoromethane sulfonate (6.7 μl, 0.0336 mmols) were added, at room temperature, to 2TMS·A <sup>Bz </sup>(128.7 mg, 0.336 mmol) prepared in accordance with a reference 6) (H. Vorbrggen, K. Krolikiewicz and B. Bennua, Chem., Ber., 114, 1234-1255 (1981)). The mixture was heated under reflux for 26 hours. After a saturated sodium bicarbonate solution was added to the reaction mixture, the system was extracted 3 times with methylene chloride. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl<sub>3</sub>-MeOH, 1:3) to obtain a white powder, Compound 40 (234.5 mg, 0.253 mmol, 75%).</p>
    <p>m.p. 77-78° C. (AcOEt/hexane). [α]<sub>D</sub> <sup>24</sup>−13.2° (c=1.00, CHCl<sub>3</sub>).</p>
    <p>IR ν max (KBr): 3058, 2934, 1749, 1703, 1606, 1105 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 0.99 (9H, s), 2.04 (3H, s), 2.38 (3H, s), 3.7 4, 3.85 (2H, AB, J=11 Hz), 4.31, 4.43 (2H, AB, J=11 Hz), 4. 52, 4.58 (2H, AB, J=11 Hz), 4.81 (1H, d, J=6 Hz), 5.94 (1H, d, J=6 Hz), 6.04 (1H, d, J=5 Hz), 7.18-7.61 (20H, m), 7.69 (2H, d, J=8 Hz), 7.99 (1H, s), 8.01 (2H, d, J=7 Hz), 8.56 (1H, s), 8.99 (1H, br s). <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ<sub>c</sub>: 19.1, 20.5, 2 1.5, 26.7, 64.1, 68.4, 74.0, 74.6, 77.9, 86.57, 86.64, 123.4, 127.7, 127.8, 127.9, 128.1, 128.5, 128.8, 129.6, 129.9, 132.0, 132.3, 132.6, 132.7, 133.5, 135.4, 135.5, 136.8, 142.0, 144.7, 149.6, 151.2, 152.6, 164.5, 169.8. MS(FAB) m/z: 926 (M<sup>+</sup>+H).</p>
    <p>(2) Synthesis of 3′-O-benzyl-5′-O-t-butyldiphenylsilyl-4′-p-toluenesulfonyloxymethyl-N<sup>6</sup>-benzoyladenosine (Compound 41)</p>
    <p>To a methyl alcohol solution (3.0 ml) of Compound 40 (167.9 mg, 0.182 mmol), potassium carbonate (15.0 mg, 0.109 mmol) was added at room temperature, and the mixture was stirred for 15 minute at room temperature. Concentrated hydrochloric acid was added to the reaction mixture to neutralize it, whereafter the system was extracted 3 times with methylene chloride. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl<sub>3</sub>-MeOH, 30:1) to obtain a white powder, Compound 41 (140.5 mg, 0.160 mmol, 88%).</p>
    <p>m.p. 82-83° C. (AcOEt-hexane). [α]<sub>D</sub> <sup>25</sup>−6.02° (c=0.96, CHCl<sub>3</sub>).</p>
    <p>IR ν max (KBr): 3306, 3066, 2935, 2859, 1701, 1611 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 0.98 (9H, s), 2.37 (3H, s), 3.76 (2H, s), 4. 39, 4.45 (1H, AB, J=11 Hz), 4.54 (1H, d, J=6 Hz), 4.67, 4. 76 (2H, AB, J=11 Hz), 4.85 (1H, dd, J=5, 6 Hz), 5.79 (1H, d, J=5 Hz), 7.20-7.58 (21H, m), 7.73 (2H, d, J=8 Hz), 7.80 (1H, s), 7.96 (2H, d, J=8 Hz), 8.49 (1H, s), 9.18 (1H, br s).</p>
    <p> <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ<sub>c</sub>: 19.1, 21.6, 26.8, 64.4, 68.9, 74.1, 74.6, 79.2, 86.8, 89.8, 123.1, 127.7, 127.8, 128.0, 128.2, 128.4, 1 28.6, 128.8, 129.7, 130.0, 132.1, 132.5, 132.6, 132.8, 133.4, 135.4, 135.5, 136.8, 142.1, 144.8, 149.4, 152.3, 164.5.</p>
    <p>(3) Synthesis of 3′-O-benzyl-5′-O-t-butyldiphenylsilyl-2′-O,4′-C-methylene-N<sup>6</sup>-benzyladenosine (Compound 42)</p>
    <p>In a stream of nitrogen, sodium bis(trimethylsilyl)amide (1.0 M in THF, 0.58 ml, 0.572 mmol) was added to a tetrahydrofuran solution (8.0 ml) of Compound 41 (210.5 mg, 0.238 mmol) at room temperature, and the mixture was stirred for 3 hours at room temperature. A saturated sodium bicarbonate solution was added to the reaction mixture, and then the system was extracted 3 times with methylene chloride. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl<sub>3</sub>-MeOH, 30:1) to obtain a white powder, Compound 42 (169.5 mg, 0.238 mmol, quant.).</p>
    <p>mp. 80-81° C. IR ν max (KBr): 3259, 3064, 2932, 2858, 1703, 1607 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ: 1.07 (9H, s), 3.95, 4.10 (2H, AB, J=8 Hz), 4.02 (2H, d, J=8 Hz), 4.56, 4.64 (2H, AB, J=12 Hz), 4.26 (1H, s), 4.86 (1H, s), 6.14 (1H, s), 7.26-7.70 (18H, m), 8.04 (2H, d, J=7 Hz), 8.22 (1H, s), 8.78 (1H, s), 9.18 (1H, brs).</p>
    <p> <sup>13</sup>C-NMR(CDCl<sub>3</sub>) δ<sub>c</sub>: 19.2, 26.5, 26.8, 29.7, 59.2, 72.4, 72.6, 7 6.5, 76.8, 86.7, 88.6, 123.4, 127.7, 127.8, 127.9, 128.1, 128.4, 128.8, 129.5, 130.0, 132.4, 132.5, 132.8, 133.5, 134.8, 135.2, 135.5, 135.6, 136.8, 140.4, 152.7.</p>
    <p>(4) Synthesis of 3′-O-benzyl-2′-0,4′-C-methylene-N<sup>6</sup>-benzoyladenosine (Compound 43)</p>
    <p>Tetrabutylammonium fluoride (1.0 M in THF, 1.0 ml, 1.0 mmol) was added, at room temperature, to a tetrahydrofuran solution (7.0 ml) of Compound 42 (173.6 mg, 0.244 mmol), and the mixture was stirred for 25 minutes at room temperature. The reaction mixture was distilled under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl<sub>3</sub>-MeOH, 15:1) to obtain a white powder, Compound 43 (115.4 mg, 0.244 mmol, quant.).</p>
    <p>mp. 154-155° C. (Et2O). IR ν max(KBr): 3339, 2944, 1701, 1611 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ: 3.91, 4.13 (2H, AB, J=8 Hz), 3.93, 4.01 (2H, AB, J 12 Hz), 4.38 (1H, s), 4.64 (1H, s), 4.85 (1H, s), 6.08 (1H, s), 7.29 (1H, s), 7.51 (2H, d, J=8 Hz), 7.58 (1H, d, J=7 Hz), 8.05 (2H, d, J=7 Hz), 8.14 (1H, s), 8.75 (1H, s), 9.50 (1H, br s).</p>
    <p> <sup>3</sup>C-NMR(CDCl<sub>3</sub>) δ<sub>c</sub>: 57.1, 72.4, 77.0, 77.1, 86.9, 88.6, 122.9, 127.6, 128.0, 128.1, 128.4, 128.7, 132.8, 133.5, 136.9, 140.5, 149.8, 150.5, 152.8, 165.0.</p>
    <heading>EXAMPLE 5</heading> <p>(1) Synthesis of 2′-O-acetyl-3′-O-benzyl-5′-O-t-butyldiphenylsilyl-4′-p-toluenesulfonyloxymethyl-N<sup>2</sup>-isobutyrylguanosine (Compound 44)</p>
    <p>In a stream of nitrogen, a 1,2-dichloroethane solution (5.0 ml) of Compound 4 (250 mg, 0.336 mmol) and trimethylsilyltrifluoromethane sulfonate (6.7 μl, 0.0336 mmol) were added, at room temperature, to 3TMS·GiBU (146.8 mg, 0.336 mmol) prepared in accordance with the aforementioned reference 6). The mixture was heated under reflux for 15 hours. After a saturated sodium bicarbonate solution was added to the reaction mixture, the system was extracted 3 times with methylene chloride. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl<sub>3</sub>-MeOH, 30:1) to obtain a white powder, Compound 44 (213.6 mg, 0.235 mmol, 70%).</p>
    <p>m.p. 96-97° C. (AcOEt-hexane). [α]<sub>D</sub> <sup>24</sup>−11.09° (c=0.97, CHCl<sub>3</sub>).</p>
    <p>IR ν max (KBr): 3152, 3065, 2934, 1746, 1681, 1606 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) d: 0.96 (9H, s), 1.10 (3H, d, J=9 Hz), 1.13 (3H, d, J=9 Hz), 1.98 (3H, s), 2.36 (3H, s), 2.48 (1H, m), 3.65, 3.72 (2H, AB, J=11 Hz), 4.23, 4.43 (2H, AB, J=11 Hz), 4.47 (2H, s), 4.63 (1H, d, J=6 Hz), 5.74 (1H, t, J=6 Hz), 5.96 (1H, d, J=6 Hz), 7.14-7.68 (20H, m), 9.15 (1H, s), 12. 20 (1H, s).</p>
    <p> <sup>13</sup>C-NMR(CDCl<sub>3</sub>) δ<sub>c</sub>: 19.1, 19.3, 19.4, 20.8, 21.9, 27.0, 27.2, 36. 5, 64.5, 68.9, 74.4, 74.9, 76.7, 86.1, 86.7, 122.0, 127.6, 12 7.7, 127.9, 128.1, 128.3, 128.4, 128.8, 130.1, 130.4, 132.3, 132.7, 132.9, 135.7, 135.8, 137.3, 137.8, 145.2, 147.8, 148.5, 156.2, 170.2, 178.8.</p>
    <p>(2) Synthesis of 3′-O-benzyl-5′-O-t-butyldiphenylsilyl-4′-p-toluenesulfonyloxymethyl-N<sup>2 </sup>isobutyrylguanosine (Compound 45)</p>
    <p>To a methyl alcohol solution (3.0 ml) of Compound 44 (137.0 mg, 0.151 mmol), potassium carbonate (15.8 mg, 0.113 mmol) was added at room temperature, and the mixture was stirred for 45 minutes at room temperature. Concentrated hydrochloric acid was added to the reaction mixture to neutralize it, whereafter the system was extracted 3 times with methylene chloride. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl<sub>3</sub>-MeOH, 30:1) to obtain a white powder, Compound 45 (83.4 mg, 0.097 mmol, 64%).</p>
    <p>mp. 102-103° C. (AcOEt-hexane). [α]<sub>D</sub> <sup>25</sup>−2.00° (c=0.40, CHCl<sub>3</sub>). IR ν max(KBr): 3166, 2932, 1684, 1607 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 0.90 (9H, s), 1.09 (3H, d, J=7 Hz), 1.13 (3H, d, J=7 Hz), 2.30 (1H, m), 2.37 (3H, s), 3.71, 3.76 (2H, AB, J=11 Hz), 4.32, 4.48 (2H, AB, J=11 Hz), 4.35 (1H, d, J=6 Hz), 4.63, 4.90 (2H, AB, J=12 Hz), 4.96 (1H, t, J=6H z), 5.67 (1H, d, J=7 Hz), 7.17-7.71 (20H, m), 8.82 (1H, s), 12.05 (1H, br s).</p>
    <p> <sup>13</sup>C-NMR(CDCl<sub>3</sub>) δ<sub>c</sub>: 18.7, 19.0, 21.6, 26.5, 36.2, 63.5, 69.1, 73.7, 74.3, 78.8, 86.2, 89.5, 127.7, 127.8, 128.0, 128.1, 128.5, 129.7, 130.0, 132.0, 132.6, 132.7, 135.3, 135.4, 137.4, 138.2, 144.8, 146.9, 155.5, 178.5.</p>
    <p>(3) Synthesis of 3′-O-benzyl-5′-O-t-butyldiphenylsilyl-2′-O,4′-C-methylene-N<sup>2</sup>-isobutyrylguanosine (Compound 46)</p>
    <p>In a stream of nitrogen, sodium bis(trimethylsilyl)amide (1.0 M in THF, 0.31 ml, 0.315 mmol) was added to a tetrahydrofuran solution (3.0 ml) of Compound 45 (92.1 mg, 0.102 mmol) at room temperature, and the mixture was stirred for 3 hours at room temperature. A saturated sodium bicarbonate solution was added to the reaction mixture, and then the system was extracted 3 times with methylene chloride. The organic phase was washed with a saturated sodium chloride solution, and then dried over sodium sulfate. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (CHCl<sub>3</sub>-MeOH, 25:1) to obtain a white powder, Compound 46 (31.4 mg, 0.160 mmol, 44%).</p>
    <p>mp. 99-100° C. IR ν max(KBr): 3162, 3068, 2932, 1683, 1610 cm<sup>1</sup>.</p>
    <p> <sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ: 1.06 (9H, s), 1.25 (3H, d, J=7 Hz), 1.27 (3H, d, J=7 Hz), 2.64 (1H, m), 3.83, 4.01 (2H, AB, J=8 Hz), 3.97 (2H, d, J=7 Hz), 4.18 (1H, s), 4.51 (1H, s), 4.54 (2H, d, J=2 Hz), 5.77 (1H, s), 7.17-7.42 (5H, m), 7.64-7.72 (10H, m), 7.84 (1H, s), 9.03 (1H, s), 12.08 (1H, br s).</p>
    <p> <sup>13</sup>C-NMR(CDCl<sub>3</sub>) δ<sub>c</sub>: 18.9, 19.0, 19.1, 26.5, 26.7, 36.4, 59.1, 72.4, 72.5, 76.8, 77.5, 86.3, 88.3, 121.7, 127.6, 127.7, 127. 8, 127.9, 128.1, 128.4, 129.6, 130.0, 132.36, 132.42, 134.8, 135.45, 135.54, 135.8, 136.8, 146.8, 147.7, 155.4, 178.6.</p>
    <p>(4) Synthesis of 3′O-benzyl-2′-O,4′-C-methylene-N<sup>2</sup>-isobutyrylguanosine (Compound 47)</p>
    <p>Tetrabutylammonium fluoride (1.0 M in THF, 0.90 ml, 0.90 mmol) was added, at room temperature, to a tetrahydrofuran solution (3.0 ml) of Compound 46 (41.3 mg, 0.060 mmol), and the mixture was stirred for 1 hour at room temperature. The reaction mixture was distilled under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOH-EtOH, 20:1) to obtain a white powder, Compound 47 (27.1 mg, 0.060 mmol, quant.).</p>
    <p>mp. 228-229° C.(Et2O). [α]<sub>D</sub> <sup>25</sup>+32.90° (c=0.875, CHCl<sub>3</sub>).</p>
    <p>IR ν max (KBr): 3162, 2934, 1683, 1608 cm<sup>−1</sup>.</p>
    <p> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 1.24 (3H, d, J=7 Hz), 1.26 (3H, d, J=7 Hz), 2.76 (1H, m), 3.83, 4.03 (2H, AB, J=8 Hz), 3.92, 4.02 (2H, AB, J=13 Hz), 4.33 (1H, s), 4.55 (1H, s), 4.62 (2H, s), 5.80 (1H, s), 7.25 (5H, s), 7.91 (1H, s), 9.85 (1H, s), 12.05 (1H, s).</p>
    <p> <sup>13</sup>C-NMR (CDCl<sub>3</sub>) δ<sub>c</sub>: 19.19, 19.25, 36.4, 57.4, 72.5, 77.0, 77.5, 86.5, 88.8, 121.0, 127.8, 128.1, 128.2, 128.3, 128.4, 128.6, 137.1, 137.5, 147.5, 148.2, 155.7, 179.9.</p>
    <heading>EXAMPLE 6</heading> <heading>Synthesis of Oligonucleotide Analogue</heading> <p>
      <chemistry> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00016.png"> <img id="EMI-C00016" file="US06770748-20040803-C00016.TIF" wi="213.1353" he="307.00215" img-content="chem" img-format="tif" alt="Figure US06770748-20040803-C00016" src="//patentimages.storage.googleapis.com/US6770748B2/US06770748-20040803-C00016.png" class="patent-full-image" width="852" height="1228"> </a> </div>
        <attachments> <attachment idref="CHEMCDX-00016" attachment-type="cdx" file="US06770748-20040803-C00016.CDX"> </attachment> <attachment idref="CHEMMOL-00016" attachment-type="mol" file="US06770748-20040803-C00016.MOL"> </attachment> </attachments> </chemistry> </p>
    <p>(1) 3′-O-[2-cyanoethoxy(diisopropylamino)phosphino]-5′-O-(4,4′-dimethoxytrityl)-2′-0,4′-methanouridine (Compound 21)</p>
    <p>Compound 8 (200 mg, 0.31 mmol) and diisopropylammonium tetrazolide (39.6 mg, 0.23 mmol) were subjected to azeotropy with anhydrous CH<sub>3</sub>CN three times, and then the system was converted into an anhydrous CH<sub>3</sub>CN-anhydrous THF solution (3:1, 4 ml). In a stream of nitrogen, 2-cyanoethyl N,N,N′,N′-tetraisopropylphosphorodiamidite (0.12 ml, 0.37 mmol) was added, and the mixture was stirred for 90 minutes at room temperature. The solvents were distilled off under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (AcOEt:hexane:Et<sub>3</sub>N 75:25:1). Then, the purified product was reprecipitated from AcOEt-hexane to obtain an amidite compound 21 (181 mg, 0.25 mmol, 81%).</p>
    <p>m.p. 71-74° C. (AcOEt-hexane). <sup>31</sup>P-NMR (CDCl<sub>3</sub>): δ 149.6, 149.5, 149.4, 149.3, 149.2.</p>
    <p>(2) General Synthesis of Oligonucleotide Analogues</p>
    <p>The synthesis of an oligomer was performed by means of Pharmacia's DNA synthesizer, Gene Assembler Plus, on a 0.2 μmol scale. The concentrations of solvents, reagents, and phosphoramidite were the same as for the synthesis of natural DNA. A DMTr group of 5′-O-DMTr-thymidine (0.2 μmol) having a 3′-hydroxyl group bound to a CPG support was deprotected with trichloroacetic acid. On its 5′-hydroxyl group, condensation reaction was repeated using an amidite comprising four nucleic acid bases for natural DNA synthesis and Compound 21 to synthesize oligonucleotide analogues of respective sequences. The synthetic cycle was as follows:</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="217pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Synthetic cycle (0.2 μmol scale)</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="4"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="21pt" align="left"> </colspec> <colspec colname="2" colwidth="49pt" align="left"> </colspec> <colspec colname="3" colwidth="133pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">1)</td>
                <td class="description-td">Detritylation</td>
                <td class="description-td">1% CCl<sub>3</sub>COOH in CH<sub>2</sub>ClCH<sub>2</sub>Cl, 6 sec</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">2)</td>
                <td class="description-td">Coupling</td>
                <td class="description-td">0.1 M phosphoramidite (25 equiv.),</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">0.5 M 1H-tetrazole (500 equiv.) in MeCN,</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">2 min</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">3)</td>
                <td class="description-td">Capping</td>
                <td class="description-td">3% 4-(dimethylamino)pyridine, 10% Ac<sub>2</sub>O,</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">in MeCN, 18 sec</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">4)</td>
                <td class="description-td">Oxidation</td>
                <td class="description-td">0.01 M I<sub>2</sub> in 2,4,6-collidine/H<sub>2</sub>O/MeCN</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">(1:5:11), 6 sec</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>The synthesized oligomer was cleaved from the support by treatment with concentrated aqueous ammonia in the customary manner. At the same time, the protective cyanoethyl group was detached from the phosphorus atom, and the protective groups for the adenine, guanine and cytosine were also removed.</p>
    <p>The resulting 5′-O-dimethoxytritylated oligonucleotide analogue was rid of the DMTr group by use of 5 ml trifluoroacetic acid on a reversed phase chromatographic column (Millipore, Oligo-Pak™SP), and further purified to obtain the desired oligonucleotide analogue.</p>
    <p>In accordance with the foregoing method for general synthesis, the following oligonucleotide analogues were synthesized:</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="35pt" align="center"> </colspec> <colspec colname="2" colwidth="182pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">(2)</td>
                <td class="description-td">5′-GCGXTTTTTGCT-3′ (XT5) (SEQ ID NO:2)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Yield 0.06 μmol (30% yield)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">(3)</td>
                <td class="description-td">5′-GCGTTXTTTGCT-3′ (T2XT3) (SEQ ID NO:3)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Yield 0.05 μmol (25% yield)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">(4)</td>
                <td class="description-td">5′-GCGTTTXTTGCT-3′ (T3XT2) (SEQ ID NO:4)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Yield 0.03 μmol (15% yield)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">(5)</td>
                <td class="description-td">5′-GCGTTTTTXGCT-3′ (T5X) (SEQ ID NO:5)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Yield 0.06 μmol (30% yield)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">(6)</td>
                <td class="description-td">5′-GCGXXTTTTGCT-3′ (X2T4) (SEQ ID NO:6)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Yield 0.06 μmol (30% yield)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">(7)</td>
                <td class="description-td">5′-GCGTTXXTTGCT-3′ (T2X2T2) (SEQ ID NO:7)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Yield 0.05 μmol (25% yield)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">(8)</td>
                <td class="description-td">5′-GCGTTTTXXGCT-3′ (T4X2) (SEQ ID NO:8)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Yield 0.06 μmol (30% yield)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">(9)</td>
                <td class="description-td">5′-GCGXXXXXXGCT-3′ (X6) (SEQ ID NO:9)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Yield 0.06 μmol (30% yield)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">(11) </td>
                <td class="description-td">5′-GTTTTTTTTTXXC-3′ (X2) (SEQ ID NO:11)</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Yield 0.07 μmol (35% yield)</td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <heading>EXPERIMENTAL EXAMPLE 1</heading> <heading>Measurement of Melting Temperature (Tm)</heading> <p>The melting temperatures (Tm's) of annealing products between antisense strands, which were the various oligonucleotide analogues synthesized in Example 2, and natural DNA- or RNA-based sense strands were measured to investigate the hybridizing ability of the oligonucleotide analogues of the present invention for complementary DNA and RNA.</p>
    <p>Each sample solution (500 μL) with end concentrations of 100 mM NaCl, 10 mM sodium phosphate buffer (pH 7.2), 4 μM antisense strand, and 4 μM sense strand, respectively, was bathed in boiling water, and slowly cooled to room temperature over the course of 10 hours. The sample solution was gradually cooled to 5° C., kept at 5° C. for a further period of 20 minutes, and then started to be measured, with a stream of nitrogen being passed through a cell chamber of a spectrophotometer (UV-2100PC, Shimadzu) for prevention of moisture condensation. The sample temperature was raised at a rate of 0.2° C./minute until 90° C., and the ultraviolet absorption at 260 nm was measured at intervals of 0.1° C. To prevent changes in the sample concentration with increases in the temperature, the cell was provided with a closure, and a drop of a mineral oil was applied onto the surface of the sample solution during measurement.</p>
    <p>The results are shown in the following table.</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="273pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 1</td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Melting Temperatures (Tm's) of Antisense</td>
              </tr> <tr class="description-tr"> <td class="description-td">Oligonucleotide Analogues for Complementary</td>
              </tr> <tr class="description-tr"> <td class="description-td">DNA and RNA</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="105pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="84pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Tm for</td>
                <td class="description-td">Tm for</td>
              </tr> <tr class="description-tr"> <td class="description-td">Antisense</td>
                <td class="description-td">complementary DNA<sup>a)</sup> </td>
                <td class="description-td">complementary RNA<sup>b)</sup> </td>
              </tr> <tr class="description-tr"> <td class="description-td">molecule</td>
                <td class="description-td">(ΔTm/mod.)</td>
                <td class="description-td">(ΔTm/mod.)</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">5′-GCGTTTTTTTGCT-3′</td>
                <td class="description-td">47° C.</td>
                <td class="description-td">45° C.</td>
              </tr> <tr class="description-tr"> <td class="description-td">(natural) (SEQ ID NO:1)</td>
              </tr> <tr class="description-tr"> <td class="description-td">5′-GCGXTTTTTGCT-3′</td>
                <td class="description-td">50° C. (+3° C.)</td>
                <td class="description-td">49° C. (+4° C.)</td>
              </tr> <tr class="description-tr"> <td class="description-td">(XT6) (SEQ ID NO:2)</td>
              </tr> <tr class="description-tr"> <td class="description-td">5′-GCGTTXTTTGCT-3′</td>
                <td class="description-td">49° C. (+2° C.)</td>
                <td class="description-td">49° C. (+4° C.)</td>
              </tr> <tr class="description-tr"> <td class="description-td">(T2XT3) (SEQ ID NO:3)</td>
              </tr> <tr class="description-tr"> <td class="description-td">5′-GCGTTTCTTGCT-3′</td>
                <td class="description-td">49° C. (+2° C.)</td>
                <td class="description-td">50° C. (+5° C.)</td>
              </tr> <tr class="description-tr"> <td class="description-td">(T3XT2) (SEQ ID NO:4)</td>
              </tr> <tr class="description-tr"> <td class="description-td">5′-GCGTTTTTXGCT-3′</td>
                <td class="description-td">52° C. (+4° C.)</td>
                <td class="description-td">51° C. (+6° C.)</td>
              </tr> <tr class="description-tr"> <td class="description-td">(T5X) (SEQ ID NO:5)</td>
              </tr> <tr class="description-tr"> <td class="description-td">5′-GCGXXTTTTGCT-3′</td>
                <td class="description-td">51° C. (+2° C.)</td>
                <td class="description-td">53° C. (+4° C.)</td>
              </tr> <tr class="description-tr"> <td class="description-td">(X2T4) (SEQ ID NO:6)</td>
              </tr> <tr class="description-tr"> <td class="description-td">5′-GCGTTXXTTGCT-3′</td>
                <td class="description-td">49° C. (+1° C.)</td>
                <td class="description-td">53° C. (+4° C.)</td>
              </tr> <tr class="description-tr"> <td class="description-td">(T2X2T2) (SEQ ID NO:7)</td>
              </tr> <tr class="description-tr"> <td class="description-td">5′-GCGTTTTXXGCT-3′</td>
                <td class="description-td">54° C. (+3.5° C.)</td>
                <td class="description-td">55° C. (+5° C.)</td>
              </tr> <tr class="description-tr"> <td class="description-td">(T4X2) (SEQ ID NO:8)</td>
              </tr> <tr class="description-tr"> <td class="description-td">5′-GCGXXXXXXGCT-3′</td>
                <td class="description-td">58° C. (+1.8° C.)</td>
                <td class="description-td">71° C. (+4.3° C.)</td>
              </tr> <tr class="description-tr"> <td class="description-td">(X6) (SEQ ID NO:9)</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="left" class="description-td" colspan="3"> <sup>a)</sup>3′-CGCAAAAAACGA-5′ (SEQ ID NO:12) </td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="left" class="description-td" colspan="3"> <sup>b)</sup>3′-r(CGCAAAAAACGA) (SEQ ID NO:12) </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>As shown in the table, in the case of the oligomer having one or two units (X) of the nucleoside analogue of the present invention (general formula (Ia)) introduced into a natural DNA strand, the ability to hybridize with the complementary DNA oligomer, evaluated by the Tm, rose by 2 to 7 degrees (about 2 degrees per modified residue) as compared with the natural strand. With the oligomer having all T's substituted by X's (X6), the increase in the ability was as high as 11 degrees. When the ability to hybridize with complementary RNA was evaluated, the oligomer incorporating one or two X's had an increase in Tm of 4-10 degrees (4 to 6 degrees per modified residue) over the natural strand. In the case of X6, the ability to hybridize with complementary RNA was further enhanced, showing an increase in Tm of more than 25 degrees (4 degrees per modified residue). There have been no examples of analogues undergoing such increases in Tm as compared with natural strands, and the affinity of the claimed oligomer was higher for RNA than for DNA. These facts mean that the oligonucleotide analogue composed of the bicyclooligonucleoside analogue of the present invention has extremely high performance as an antisense molecule, and is useful as a material for pharmaceuticals.</p>
    <heading>EXPERIMENTAL EXAMPLE 2</heading> <heading>Measurement of Nuclease Resistance</heading> <p>A buffer solution (0.003 U/ml, 400 μl) of a snake venom phosphodiesterase was mixed with a buffer solution (10 μM, 400 μl) of the oligonucleotide held at 37° C. for 15 minutes. The mixed solution was placed in a quartz cell (800 μl) kept at 37° C., and increases in the ultraviolet absorption (260 nm) due to the decomposition of the oligonucleotide were measured over time by means of SHIMADZU UV-2100PC. The buffer used comprised 0.1 M Tris-HCl (pH 8.6), 0.1 M NaCl, and 14 mM MgCl<sub>2</sub>, and was sufficiently degassed before measurement.</p>
    <p>Measurement of half-life (t<sub>½</sub>):</p>
    <p>A calculation was made of the average of the values of the UV absorption measured at the start of measurement (t=0) and that measured at the time when no increase in this parameter was noted. The time corresponding to this average was designated as the half-life (t<sub>½</sub>).</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="147pt" align="left"> </colspec> <colspec colname="2" colwidth="70pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Oligonucleotide sequence</td>
                <td class="description-td">t<sub>½</sub> (seconds)</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">5′-GTTTTTTTTTTTC-3′ (natural type)</td>
                <td class="description-td">260</td>
              </tr> <tr class="description-tr"> <td class="description-td">(SEQ ID NO:10)</td>
              </tr> <tr class="description-tr"> <td class="description-td">5′-GTTTTTTTTT-XX-C-3′ (X2)</td>
                <td class="description-td">850</td>
              </tr> <tr class="description-tr"> <td class="description-td">(SEQ ID NO:11)</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p>Charts showing the time course of the ultraviolet absorption are presented as FIG. 1 (natural strand) and FIG. 2 (X2). The ultraviolet absorption reached a plateau in about 30 minutes for the natural strand, and about 90 minutes for X2, after initiation of the enzyme reaction.</p>
    <heading>INDUSTRIAL APPLICABILITY</heading> <p>The use of this analogue provides an oligonucleotide analogue antisense molecule, which is minimally hydrolyzable with an enzyme in vivo, has a high sense strand binding ability, and is easily synthesized.</p>
    <p>
      <tables> <table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="441pt" align="left"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">                  </td>
              </tr> <tr class="description-tr"> <td class="description-td">#             SEQUENCE LISTING </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;160&gt; NUMBER OF SEQ ID NOS: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 1 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 1 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gly Cys Gly Thr Thr Thr Thr Thr Thr Gly Cy </td>
              </tr> <tr class="description-tr"> <td class="description-td">#s Thr </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 2 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;221&gt; NAME/KEY: misc_feature </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;222&gt; LOCATION: (4)..(4) </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: Xaa can be any natural </td>
              </tr> <tr class="description-tr"> <td class="description-td">#ly occurring amino acid </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 2 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gly Cys Gly Xaa Thr Thr Thr Thr Thr Gly Cy </td>
              </tr> <tr class="description-tr"> <td class="description-td">#s Thr </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 3 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;221&gt; NAME/KEY: misc_feature </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;222&gt; LOCATION: (6)..(6) </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: Xaa can be any natural </td>
              </tr> <tr class="description-tr"> <td class="description-td">#ly occurring amino acid </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 3 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gly Cys Gly Thr Thr Xaa Thr Thr Thr Gly Cy </td>
              </tr> <tr class="description-tr"> <td class="description-td">#s Thr </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 4 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;221&gt; NAME/KEY: misc_feature </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;222&gt; LOCATION: (7)..(7) </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: Xaa can be any natural </td>
              </tr> <tr class="description-tr"> <td class="description-td">#ly occurring amino acid </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 4 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gly Cys Gly Thr Thr Thr Xaa Thr Thr Gly Cy </td>
              </tr> <tr class="description-tr"> <td class="description-td">#s Thr </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 5 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;221&gt; NAME/KEY: misc_feature </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;222&gt; LOCATION: (9)..(9) </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: Xaa can be any natural </td>
              </tr> <tr class="description-tr"> <td class="description-td">#ly occurring amino acid </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 5 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gly Cys Gly Thr Thr Thr Thr Thr Xaa Gly Cy </td>
              </tr> <tr class="description-tr"> <td class="description-td">#s Thr </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 6 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;221&gt; NAME/KEY: misc_feature </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;222&gt; LOCATION: (4)..(5) </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: Xaa can be any natural </td>
              </tr> <tr class="description-tr"> <td class="description-td">#ly occurring amino acid </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 6 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gly Cys Gly Xaa Xaa Thr Thr Thr Thr Gly Cy </td>
              </tr> <tr class="description-tr"> <td class="description-td">#s Thr </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 7 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;221&gt; NAME/KEY: misc_feature </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;222&gt; LOCATION: (6)..(7) </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: Xaa can be any natural </td>
              </tr> <tr class="description-tr"> <td class="description-td">#ly occurring amino acid </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 7 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gly Cys Gly Thr Thr Xaa Xaa Thr Thr Gly Cy </td>
              </tr> <tr class="description-tr"> <td class="description-td">#s Thr </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 8 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;221&gt; NAME/KEY: misc_feature </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;222&gt; LOCATION: (8)..(9) </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: Xaa can be any natural </td>
              </tr> <tr class="description-tr"> <td class="description-td">#ly occurring amino acid </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 8 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gly Cys Gly Thr Thr Thr Thr Xaa Xaa Gly Cy </td>
              </tr> <tr class="description-tr"> <td class="description-td">#s Thr </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 9 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;221&gt; NAME/KEY: misc_feature </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;222&gt; LOCATION: (4)..(9) </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: Xaa can be any natural </td>
              </tr> <tr class="description-tr"> <td class="description-td">#ly occurring amino acid </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 9 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gly Cys Gly Xaa Xaa Xaa Xaa Xaa Xaa Gly Cy </td>
              </tr> <tr class="description-tr"> <td class="description-td">#s Thr </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 10 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 13 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gly Thr Thr Thr Thr Thr Thr Thr Thr Thr Th </td>
              </tr> <tr class="description-tr"> <td class="description-td">#r Thr Cys </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 11 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 13 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;221&gt; NAME/KEY: misc_feature </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;222&gt; LOCATION: (11)..(12) </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: Xaa can be any natural </td>
              </tr> <tr class="description-tr"> <td class="description-td">#ly occurring amino acid </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 11 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gly Thr Thr Thr Thr Thr Thr Thr Thr Thr Xa </td>
              </tr> <tr class="description-tr"> <td class="description-td">#a Xaa Cys </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;210&gt; SEQ ID NO 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;211&gt; LENGTH: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;212&gt; TYPE: PRT </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;213&gt; ORGANISM: Artificial </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;220&gt; FEATURE: </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;223&gt; OTHER INFORMATION: synthetic </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">&lt;400&gt; SEQUENCE: 12 </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Gly Cys Ala Ala Ala Ala Ala Ala Cys Gl </td>
              </tr> <tr class="description-tr"> <td class="description-td">#y Ala </td>
              </tr> <tr class="description-tr"> <td class="description-td">1               5   </td>
              </tr> <tr class="description-tr"> <td class="description-td">#                10</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5859221">US5859221</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 1995</td><td class="patent-data-table-td patent-date-value">Jan 12, 1999</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Hybrid dna, rna; nuclease resistant</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6268490">US6268490</a></td><td class="patent-data-table-td patent-date-value">Mar 9, 1998</td><td class="patent-data-table-td patent-date-value">Jul 31, 2001</td><td class="patent-data-table-td ">Takeshi Imanishi</td><td class="patent-data-table-td ">Bicyclonucleoside and oligonucleotide analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1997047636A2?cl=en">WO1997047636A2</a></td><td class="patent-data-table-td patent-date-value">Jun 3, 1997</td><td class="patent-data-table-td patent-date-value">Dec 18, 1997</td><td class="patent-data-table-td ">Altmann Karl Heinz</td><td class="patent-data-table-td ">Intermediates for oligonucleotide synthesis</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Altmann et al., "<a href='http://scholar.google.com/scholar?q="6%27-Carbon-Substituted+Carbocyclic+Analogs+of+2%27-Deoxyribonucleosides-Synthesis+and+Effect+on+DNA%2FRNA+Duplex+Stability%2C"'>6'-Carbon-Substituted Carbocyclic Analogs of 2'-Deoxyribonucleosides-Synthesis and Effect on DNA/RNA Duplex Stability,</a>" Tetrahedron, 52(39), 12699-12722 (1996).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Altmann et al., "<a href='http://scholar.google.com/scholar?q="6%E2%80%B2-Carbon-Substituted+Carbocyclic+Analogs+of+2%E2%80%B2-Deoxyribonucleosides%E2%80%94Synthesis+and+Effect+on+DNA%2FRNA+Duplex+Stability%2C"'>6′-Carbon-Substituted Carbocyclic Analogs of 2′-Deoxyribonucleosides—Synthesis and Effect on DNA/RNA Duplex Stability,</a>" Tetrahedron, 52(39), 12699-12722 (1996).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Beaucage et al. (I), "<a href='http://scholar.google.com/scholar?q="Advances+in+the+Synthesis+of+Oligonucleotides+by+the+Phosphoramidite+Approach%2C"'>Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach,</a>" (Tetrahedron Report No. 309) Tetrahedron, 48(12), 2223-2311 (1992).*</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Beaucage et al. (II), "<a href='http://scholar.google.com/scholar?q="The+Synthesis+of+Modified+Oligonucleotides+by+the+Phosphoramidite+Approach+and+Their+Applications%2C"'>The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications,</a>" Tetrahedron, 49(28), 6123-6194 (1993).*</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Beaucage, "<a href='http://scholar.google.com/scholar?q="Oligonucleotide+Synthesis-Phosphoramidite+Approach%2C"'>Oligonucleotide Synthesis-Phosphoramidite Approach,</a>" Ch. 3 in Methods in Molecular Biology, vol. 20: Protocols for Oligonucleotide and Analogues, S. Agrawal (ed.), 1993, Humana Press, Totowa, NJ, pp. 33-61.*</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Beaucage, "<a href='http://scholar.google.com/scholar?q="Oligonucleotide+Synthesis%E2%80%94Phosphoramidite+Approach%2C"'>Oligonucleotide Synthesis—Phosphoramidite Approach,</a>" Ch. 3 in Methods in Molecular Biology, vol. 20: Protocols for Oligonucleotide and Analogues, S. Agrawal (ed.), 1993, Humana Press, Totowa, NJ, pp. 33-61.*</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Herdewijn, "<a href='http://scholar.google.com/scholar?q="Targeting+RNA+with+Conformationally+Restricted+Oligonucleotides%2C"'>Targeting RNA with Conformationally Restricted Oligonucleotides,</a>" Liebigs Annalen, (Issue No. 9), 1337-1348 (Sep., 1996).</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Lehninger et al., Principles of Biochemistry, Second Edition, Worth Publishers, 1993, only pp. 324-327 supplied.*</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nielsen et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+and+Chemoselective+Activation+of+Phenyl+3%2C5-Di-O-benzyl-2-O%2C4-C-methylene-1-thio-beta-D-ribofuranoside%3A+A+Key+Synthon+Towards+alpha-LNA%2C"'>Synthesis and Chemoselective Activation of Phenyl 3,5-Di-O-benzyl-2-O,4-C-methylene-1-thio-beta-D-ribofuranoside: A Key Synthon Towards alpha-LNA,</a>" Chemical Communications, (Issue No. 23), 2645-2646 (Dec. 7, 1998).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nielsen et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+and+Chemoselective+Activation+of+Phenyl+3%2C5-Di-O-benzyl-2-O%2C4-C-methylene-1-thio-%CE%B2-D-ribofuranoside%3A+A+Key+Synthon+Towards+%CE%B1-LNA%2C"'>Synthesis and Chemoselective Activation of Phenyl 3,5-Di-O-benzyl-2-O,4-C-methylene-1-thio-β-D-ribofuranoside: A Key Synthon Towards α-LNA,</a>" Chemical Communications, (Issue No. 23), 2645-2646 (Dec. 7, 1998).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Obika et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+of+2%27-O%2C4%27-C+-Methyleneuridine+and+-cytidine.+Novel+Bicyclic+Nucleosides+Having+a+Fixed+C3+%2C+-endo+Sugar+Puckering%2C"'>Synthesis of 2'-O,4'-C -Methyleneuridine and -cytidine. Novel Bicyclic Nucleosides Having a Fixed C3 , -endo Sugar Puckering,</a>" Tetrahedron Letters, 38(50), 8735-8738 (Dec. 15, 1997).</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Obika et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+of+2%E2%80%B2-O%2C4%E2%80%B2-C+-Methyleneuridine+and+-cytidine.+Novel+Bicyclic+Nucleosides+Having+a+Fixed+C3+%2C+-endo+Sugar+Puckering%2C"'>Synthesis of 2′-O,4′-C -Methyleneuridine and -cytidine. Novel Bicyclic Nucleosides Having a Fixed C3 , -endo Sugar Puckering,</a>" Tetrahedron Letters, 38(50), 8735-8738 (Dec. 15, 1997).</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Sanghvi, "<a href='http://scholar.google.com/scholar?q="Heterocyclic+Base+Modifications+in+Nucleic+Acids+and+Their+Applications+in+Antisense+Oligonuceotides%2C"'>Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonuceotides,</a>" Ch. 15 in Antisense Research and Applications, Crooke &amp; LeBleu (eds.), CRC Press, Boca Raton, FL, 1993, pp. 273-288.*</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Singh, et al., LNA (locked Nucleic Acids): Synthesis and High-Affinity Nucleic Acid Recognition, Chemical Communications, 1998, 455-456, 4 (Feb. 21, 1998).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7589190">US7589190</a></td><td class="patent-data-table-td patent-date-value">Nov 9, 2005</td><td class="patent-data-table-td patent-date-value">Sep 15, 2009</td><td class="patent-data-table-td ">Enzon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Potent LNA oligonucleotides for the inhibition of HIF-1A expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7615619">US7615619</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 13, 2003</td><td class="patent-data-table-td patent-date-value">Nov 10, 2009</td><td class="patent-data-table-td ">Takeshi Imanishi</td><td class="patent-data-table-td ">Triplexes/regulatory sequences for controlling gene expression; antisense agents; nuclease resistance; for detection of particular genes for initiation of amplification; 3&#39;-O-[2-Cyanoethoxy-(diisopropylamino)phosphino]-5&#39;-deoxy-5&#39;-(4-methoxytriphenyl-methylamino)-5-methyl-2&#39;-O,4&#39;-C-methyleneuridine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7737264">US7737264</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 4, 2003</td><td class="patent-data-table-td patent-date-value">Jun 15, 2010</td><td class="patent-data-table-td ">Enzon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligomeric compounds for the modulation HIF-1α expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7750131">US7750131</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 19, 2009</td><td class="patent-data-table-td patent-date-value">Jul 6, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">(1R,3R,4R,7S)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4&#39;-dimethoxytrityl)oxy-ethyl]-3-(uracil-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane; useful for enhancing properties of oligomeric compounds including nuclease resistance</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7846911">US7846911</a></td><td class="patent-data-table-td patent-date-value">Oct 15, 2009</td><td class="patent-data-table-td patent-date-value">Dec 7, 2010</td><td class="patent-data-table-td ">Enzon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">hypoxia-inducible factor-1 alpha (HIP-1 alpha); nucleosides, Locked Nucleic Acids; treating kidney cancer, melanoma, glioblastoma and prostate cancer, and pre-eclampsia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7939507">US7939507</a></td><td class="patent-data-table-td patent-date-value">Jun 3, 2009</td><td class="patent-data-table-td patent-date-value">May 10, 2011</td><td class="patent-data-table-td ">Enzon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Potent LNA oligonucleotides for the inhibition of HIF-1a expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8058255">US8058255</a></td><td class="patent-data-table-td patent-date-value">Jun 15, 2009</td><td class="patent-data-table-td patent-date-value">Nov 15, 2011</td><td class="patent-data-table-td ">Applied Biosystems, Llc</td><td class="patent-data-table-td ">Methods and compositions concerning siRNA&#39;s as mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8084437">US8084437</a></td><td class="patent-data-table-td patent-date-value">Nov 27, 2007</td><td class="patent-data-table-td patent-date-value">Dec 27, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for treating hypercholesterolemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8093222">US8093222</a></td><td class="patent-data-table-td patent-date-value">Jun 4, 2009</td><td class="patent-data-table-td patent-date-value">Jan 10, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for treating hypercholesterolemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8143230">US8143230</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Mar 27, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of PCSK9</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8153365">US8153365</a></td><td class="patent-data-table-td patent-date-value">Jun 3, 2010</td><td class="patent-data-table-td patent-date-value">Apr 10, 2012</td><td class="patent-data-table-td ">Exiqon A/S</td><td class="patent-data-table-td ">Oligonucleotide analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8207140">US8207140</a></td><td class="patent-data-table-td patent-date-value">Oct 27, 2010</td><td class="patent-data-table-td patent-date-value">Jun 26, 2012</td><td class="patent-data-table-td ">Santaris Pharma A/S</td><td class="patent-data-table-td ">Oligomeric compounds for the modulation of HIF-1α expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8357670">US8357670</a></td><td class="patent-data-table-td patent-date-value">May 22, 2012</td><td class="patent-data-table-td patent-date-value">Jan 22, 2013</td><td class="patent-data-table-td ">Enzon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligomeric compounds for the modulation of HIF-1A expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8410071">US8410071</a></td><td class="patent-data-table-td patent-date-value">Apr 4, 2011</td><td class="patent-data-table-td patent-date-value">Apr 2, 2013</td><td class="patent-data-table-td ">Santaris Pharma A/S</td><td class="patent-data-table-td ">Potent LNA oligonucleotides for the inhibition of HIF-1A expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8524118">US8524118</a></td><td class="patent-data-table-td patent-date-value">Oct 13, 2010</td><td class="patent-data-table-td patent-date-value">Sep 3, 2013</td><td class="patent-data-table-td ">Samsung Electronics Co., Ltd.</td><td class="patent-data-table-td ">Nitride phosphor, method of preparing the same, and white light-emitting device using the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8524681">US8524681</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 2010</td><td class="patent-data-table-td patent-date-value">Sep 3, 2013</td><td class="patent-data-table-td ">Applied Biosystems, Llc</td><td class="patent-data-table-td ">siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8546556">US8546556</a></td><td class="patent-data-table-td patent-date-value">Nov 21, 2008</td><td class="patent-data-table-td patent-date-value">Oct 1, 2013</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc</td><td class="patent-data-table-td ">Carbocyclic alpha-L-bicyclic nucleic acid analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8586554">US8586554</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Nov 19, 2013</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of PTP1B</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8642354">US8642354</a></td><td class="patent-data-table-td patent-date-value">Nov 11, 2010</td><td class="patent-data-table-td patent-date-value">Feb 4, 2014</td><td class="patent-data-table-td ">Applied Biosystems, Llc</td><td class="patent-data-table-td ">Fluid processing device for oligonucleotide synthesis and analysis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8664190">US8664190</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2011</td><td class="patent-data-table-td patent-date-value">Mar 4, 2014</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for treating hypercholesterolemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8785617">US8785617</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2012</td><td class="patent-data-table-td patent-date-value">Jul 22, 2014</td><td class="patent-data-table-td ">Santaris Pharma A/S</td><td class="patent-data-table-td ">Oligomeric compounds for the modulation of HIF-1A expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/USRE44779">USRE44779</a></td><td class="patent-data-table-td patent-date-value">Mar 9, 1998</td><td class="patent-data-table-td patent-date-value">Feb 25, 2014</td><td class="patent-data-table-td ">Santaris Pharma A/S</td><td class="patent-data-table-td ">Bicyclonucleoside and oligonucleotide analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2314594A1?cl=en">EP2314594A1</a></td><td class="patent-data-table-td patent-date-value">Jan 27, 2007</td><td class="patent-data-table-td patent-date-value">Apr 27, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">6-modified bicyclic nucleic acid analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2332951A2?cl=en">EP2332951A2</a></td><td class="patent-data-table-td patent-date-value">Jan 27, 2007</td><td class="patent-data-table-td patent-date-value">Jun 15, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">6-modified bicyclic nucleic acid analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2363481A1?cl=en">EP2363481A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Sep 7, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2363482A1?cl=en">EP2363482A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Sep 7, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2397551A1?cl=en">EP2397551A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Dec 21, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of PCSK9</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2410053A1?cl=en">EP2410053A1</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2007</td><td class="patent-data-table-td patent-date-value">Jan 25, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2410054A1?cl=en">EP2410054A1</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2007</td><td class="patent-data-table-td patent-date-value">Jan 25, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2447274A2?cl=en">EP2447274A2</a></td><td class="patent-data-table-td patent-date-value">Oct 23, 2009</td><td class="patent-data-table-td patent-date-value">May 2, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligomeric compounds and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2458006A1?cl=en">EP2458006A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">May 30, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression APOB</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2505646A1?cl=en">EP2505646A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of CRP</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2505647A1?cl=en">EP2505647A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of DGAT2</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2505648A1?cl=en">EP2505648A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of PTP1B</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2505649A1?cl=en">EP2505649A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of GCGR</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2505650A1?cl=en">EP2505650A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of PCSK9</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2548962A1?cl=en">EP2548962A1</a></td><td class="patent-data-table-td patent-date-value">Sep 17, 2008</td><td class="patent-data-table-td patent-date-value">Jan 23, 2013</td><td class="patent-data-table-td ">Applied Biosystems, LLC</td><td class="patent-data-table-td ">Sirna sequence-independent modification formats for reducing off-target phenotypic effects in rnai, and stabilized forms thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007146511A2?cl=en">WO2007146511A2</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Dec 21, 2007</td><td class="patent-data-table-td ">Isis Pharmaceuticals Inc</td><td class="patent-data-table-td ">Compounds and methods for modulating gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008150729A2?cl=en">WO2008150729A2</a></td><td class="patent-data-table-td patent-date-value">May 22, 2008</td><td class="patent-data-table-td patent-date-value">Dec 11, 2008</td><td class="patent-data-table-td ">Isis Pharmaceuticals Inc</td><td class="patent-data-table-td ">N-substituted-aminomethylene bridged bicyclic nucleic acid analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009060281A2?cl=en">WO2009060281A2</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 2008</td><td class="patent-data-table-td patent-date-value">May 14, 2009</td><td class="patent-data-table-td ">Coley Pharm Gmbh</td><td class="patent-data-table-td ">Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009149182A1?cl=en">WO2009149182A1</a></td><td class="patent-data-table-td patent-date-value">Jun 3, 2009</td><td class="patent-data-table-td patent-date-value">Dec 10, 2009</td><td class="patent-data-table-td ">The Board Of Regents Of The University Of Texas System</td><td class="patent-data-table-td ">Modulation of gene expression through endogenous small rna targeting of gene promoters</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010091308A2?cl=en">WO2010091308A2</a></td><td class="patent-data-table-td patent-date-value">Feb 5, 2010</td><td class="patent-data-table-td patent-date-value">Aug 12, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligomeric compounds and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010115154A1?cl=en">WO2010115154A1</a></td><td class="patent-data-table-td patent-date-value">Apr 2, 2010</td><td class="patent-data-table-td patent-date-value">Oct 7, 2010</td><td class="patent-data-table-td ">Fluidigm Corporation</td><td class="patent-data-table-td ">Multi-primer amplification method for barcoding of target nucleic acids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010124231A2?cl=en">WO2010124231A2</a></td><td class="patent-data-table-td patent-date-value">Apr 23, 2010</td><td class="patent-data-table-td patent-date-value">Oct 28, 2010</td><td class="patent-data-table-td ">The Board Of Regents Of The University Of Texas System</td><td class="patent-data-table-td ">Modulation of gene expression using oligomers that target gene regions downstream of 3&#39; untranslated regions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011012136A1?cl=en">WO2011012136A1</a></td><td class="patent-data-table-td patent-date-value">Jul 16, 2010</td><td class="patent-data-table-td patent-date-value">Feb 3, 2011</td><td class="patent-data-table-td ">Exiqon A/S</td><td class="patent-data-table-td ">A method for classifying a human cell sample as cancerous</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011017521A2?cl=en">WO2011017521A2</a></td><td class="patent-data-table-td patent-date-value">Aug 5, 2010</td><td class="patent-data-table-td patent-date-value">Feb 10, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Bicyclic cyclohexose nucleic acid analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011053994A1?cl=en">WO2011053994A1</a></td><td class="patent-data-table-td patent-date-value">Nov 2, 2010</td><td class="patent-data-table-td patent-date-value">May 5, 2011</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011085102A1?cl=en">WO2011085102A1</a></td><td class="patent-data-table-td patent-date-value">Jan 6, 2011</td><td class="patent-data-table-td patent-date-value">Jul 14, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011097388A1?cl=en">WO2011097388A1</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2011</td><td class="patent-data-table-td patent-date-value">Aug 11, 2011</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Selective inhibition of polyglutamine protein expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011115818A1?cl=en">WO2011115818A1</a></td><td class="patent-data-table-td patent-date-value">Mar 10, 2011</td><td class="patent-data-table-td patent-date-value">Sep 22, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">5&#39;-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011139695A2?cl=en">WO2011139695A2</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 2011</td><td class="patent-data-table-td patent-date-value">Nov 10, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modified 5&#39; diphosphate nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011139699A2?cl=en">WO2011139699A2</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 2011</td><td class="patent-data-table-td patent-date-value">Nov 10, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">5&#39; modified nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011139702A2?cl=en">WO2011139702A2</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 2011</td><td class="patent-data-table-td patent-date-value">Nov 10, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modified nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011139911A2?cl=en">WO2011139911A2</a></td><td class="patent-data-table-td patent-date-value">Apr 29, 2011</td><td class="patent-data-table-td patent-date-value">Nov 10, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Lipid formulated single stranded rna</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011156202A1?cl=en">WO2011156202A1</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 2011</td><td class="patent-data-table-td patent-date-value">Dec 15, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Substituted 2 &#39;-amino and 2 &#39;-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011156278A1?cl=en">WO2011156278A1</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 2011</td><td class="patent-data-table-td patent-date-value">Dec 15, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Bicyclic nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012083005A2?cl=en">WO2012083005A2</a></td><td class="patent-data-table-td patent-date-value">Dec 15, 2011</td><td class="patent-data-table-td patent-date-value">Jun 21, 2012</td><td class="patent-data-table-td ">Miragen Therapeutics</td><td class="patent-data-table-td ">Microrna inhibitors comprising locked nucleotides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012109395A1?cl=en">WO2012109395A1</a></td><td class="patent-data-table-td patent-date-value">Feb 8, 2012</td><td class="patent-data-table-td patent-date-value">Aug 16, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligomeric compounds comprising bicyclic nucleotides and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013022966A1?cl=en">WO2013022966A1</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 2012</td><td class="patent-data-table-td patent-date-value">Feb 14, 2013</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Linkage modified gapped oligomeric compounds and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013022967A1?cl=en">WO2013022967A1</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 2012</td><td class="patent-data-table-td patent-date-value">Feb 14, 2013</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Gapped oligomeric compounds comprising 5&#39;-modified deoxyribonucleosides in the gap and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013154798A1?cl=en">WO2013154798A1</a></td><td class="patent-data-table-td patent-date-value">Mar 20, 2013</td><td class="patent-data-table-td patent-date-value">Oct 17, 2013</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Tricyclic nucleic acid analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013154799A1?cl=en">WO2013154799A1</a></td><td class="patent-data-table-td patent-date-value">Mar 20, 2013</td><td class="patent-data-table-td patent-date-value">Oct 17, 2013</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Tricyclic nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013184209A1?cl=en">WO2013184209A1</a></td><td class="patent-data-table-td patent-date-value">Mar 14, 2013</td><td class="patent-data-table-td patent-date-value">Dec 12, 2013</td><td class="patent-data-table-td ">Ludwig Institute For Cancer Research Ltd.</td><td class="patent-data-table-td ">Mif for use in methods of treating subjects with a neurodegenerative disorder</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014071406A1?cl=en">WO2014071406A1</a></td><td class="patent-data-table-td patent-date-value">Nov 5, 2013</td><td class="patent-data-table-td patent-date-value">May 8, 2014</td><td class="patent-data-table-td ">Pronai Therapeutics, Inc.</td><td class="patent-data-table-td ">Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014076195A1?cl=en">WO2014076195A1</a></td><td class="patent-data-table-td patent-date-value">Nov 14, 2013</td><td class="patent-data-table-td patent-date-value">May 22, 2014</td><td class="patent-data-table-td ">Santaris Pharma A/S</td><td class="patent-data-table-td ">Oligonucleotide conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014076196A1?cl=en">WO2014076196A1</a></td><td class="patent-data-table-td patent-date-value">Nov 14, 2013</td><td class="patent-data-table-td patent-date-value">May 22, 2014</td><td class="patent-data-table-td ">Santaris Pharma A/S</td><td class="patent-data-table-td ">Anti apob antisense conjugate compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014080004A1?cl=en">WO2014080004A1</a></td><td class="patent-data-table-td patent-date-value">Nov 25, 2013</td><td class="patent-data-table-td patent-date-value">May 30, 2014</td><td class="patent-data-table-td ">Santaris Pharma A/S</td><td class="patent-data-table-td ">Compositions and methods for modulation of fgfr3 expression</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S023100">536/23.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S028400">536/28.4</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S026700">536/26.7</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S027200">536/27.2</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S028100">536/28.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S027100">536/27.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S026800">536/26.8</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S026900">536/26.9</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019200000">C07H19/20</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0021000000">C07H21/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019040000">C07H19/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019100000">C07H19/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019160000">C07H19/16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019060000">C07H19/06</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H19/06">C07H19/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H19/04">C07H19/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H19/20">C07H19/20</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H19/16">C07H19/16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H19/10">C07H19/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=gPRnBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H21/00">C07H21/00</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07H19/16</span>, <span class="nested-value">C07H21/00</span>, <span class="nested-value">C07H19/10</span>, <span class="nested-value">C07H19/06</span>, <span class="nested-value">C07H19/20</span>, <span class="nested-value">C07H19/04</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Apr 9, 2013</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 1-4 IS CONFIRMED.CLAIM 5 IS DETERMINED TO BE PATENTABLE AS AMENDED.NEW CLAIMS 6-10 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 23, 2011</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 30, 2008</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20080826</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 17, 2008</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 25, 2007</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">EXIQON A/S, DENMARK</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">SANTARIS PHARMA A/S, DENMARK</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IMANISHI, TAKESHI;REEL/FRAME:018797/0512</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20070116</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U1S3lPiwG5v6ImIKq5X8FuFXxeRWg\u0026id=gPRnBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0mL4IWdJkHlTU7-YKZevj-abo3jA\u0026id=gPRnBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U3gevmoeGHKd8pE12B6iNG7kFSCSA","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Bicyclonucleoside_and_oligonucleotide_an.pdf?id=gPRnBAABERAJ\u0026output=pdf\u0026sig=ACfU3U1g6M0j8xm3EFFz_PuihBcF_Y1-KA"},"sample_url":"http://www.google.com/patents/reader?id=gPRnBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>